<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12041064</article-id><article-id pub-id-type="pmcid-ver">PMC12041064.1</article-id><article-id pub-id-type="pmcaid">12041064</article-id><article-id pub-id-type="pmcaiid">12041064</article-id><article-id pub-id-type="pmid">40045151</article-id><article-id pub-id-type="doi">10.1007/s40262-025-01492-6</article-id><article-id pub-id-type="publisher-id">1492</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5321-0816</contrib-id><name name-style="western"><surname>Kicken</surname><given-names initials="MP">M. P.</given-names></name><address><email>mart.kicken@catharinaziekenhuis.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Deenen</surname><given-names initials="MJ">M. J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van der Wekken</surname><given-names initials="AJ">A. J.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van den Borne</surname><given-names initials="BEEM">B. E. E. M.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van den Heuvel</surname><given-names initials="MM">M. M.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>ter Heine</surname><given-names initials="R">R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01qavk531</institution-id><institution-id institution-id-type="GRID">grid.413532.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0398 8384</institution-id><institution>Department of Clinical Pharmacy, </institution><institution>Catharina Hospital, </institution></institution-wrap>Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05wg1m734</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Pharmacy, </institution><institution>Radboudumc, Research Institute for Medical Innovation, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xvt9f17</institution-id><institution-id institution-id-type="GRID">grid.10419.3d</institution-id><institution-id institution-id-type="ISNI">0000000089452978</institution-id><institution>Department of Clinical Pharmacy and Toxicology, </institution><institution>Leiden University Medical Centre, </institution></institution-wrap>Leiden, The Netherlands </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cv38k47</institution-id><institution-id institution-id-type="GRID">grid.4494.d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9558 4598</institution-id><institution>Department of Pulmonology and Tuberculosis, </institution><institution>University of Groningen, University Medical Centre Groningen, </institution></institution-wrap>Groningen, The Netherlands </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01qavk531</institution-id><institution-id institution-id-type="GRID">grid.413532.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0398 8384</institution-id><institution>Department of Pulmonology, </institution><institution>Catharina Hospital, </institution></institution-wrap>Eindhoven, The Netherlands </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05wg1m734</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution>Department of Pulmonology, </institution><institution>Radboudumc, Research Institute for Medical Innovation, </institution></institution-wrap>Nijmegen, The Netherlands </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0575yy874</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution>Department of Pulmonology, </institution><institution>University Medical Center, </institution></institution-wrap>Utrecht, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>64</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">487615</issue-id><fpage>511</fpage><lpage>531</lpage><history><date date-type="accepted"><day>9</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-01 00:25:14.317"><day>01</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40262_2025_Article_1492.pdf"/><abstract id="Abs1"><p id="Par1">Precision dosing of classical cytotoxic drugs in oncology remains underdeveloped, especially in treating non-small cell lung cancer (NSCLC). Despite advancements in targeted therapy and immunotherapy, classical cytotoxic agents continue to play a critical role in NSCLC treatment. However, the current body surface area (BSA)-based dosing of these agents fails to adequately address interindividual variability in pharmacokinetics. By better considering patient characteristics, treatment outcomes can be improved, reducing risks of under-exposure and over-exposure. This narrative review explores opportunities for precision dosing for key cytotoxic agents used in NSCLC treatment: cisplatin, carboplatin, pemetrexed, docetaxel, (nab-)paclitaxel, gemcitabine, and vinorelbine. A comprehensive review of regulatory reports and an extensive literature search were conducted to evaluate current dosing practices, pharmacokinetics, pharmacodynamics, and exposure-response relationships. Our findings highlight promising developments in precision dosing, although the number of directly implementable strategies remains limited. The most compelling evidence supports using the biomarker cystatin C for more precise carboplatin dosing and adopting weekly dosing schedules for docetaxel, paclitaxel, and nab-paclitaxel. Additionally, we recommend direct implementation of therapeutic drug monitoring (TDM)-guided dosing for paclitaxel. This review stresses the urgent need to reassess conventional dosing paradigms for classical cytotoxic agents to better align with the principles of the precision dosing framework. Our recommendations show the potential of precision dosing to improve NSCLC treatment, addressing gaps in the current dosing of classical cytotoxic drugs. Given the large NSCLC patient population, optimising the dosing of these agents could significantly improve treatment outcomes and reduce toxicity for many patients.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e241"><title>Key Points</title><p>
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">Classical cytotoxic agents are vital in treating lung cancer, but conventional dosing fails to account for interindividual variability, resulting in under-exposure and over-exposure.</td></tr><tr><td align="left" colspan="1" rowspan="1">Directly implemental opportunities exist for precision dosing in lung cancer based on established pharmacokinetic and pharmacodynamic relationships.</td></tr><tr><td align="left" colspan="1" rowspan="1">Precision dosing for classical cytotoxic agents can enhance treatment efficacy, reduce toxicity, and significantly improve treatment for the large lung cancer patient population.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1"><title>Introduction</title><p id="Par2">Lung cancer is the second most common cancer in the world. In 2022, a total of 2.5 million people worldwide were diagnosed with lung cancer, followed by an estimated 1.8 million deaths that year, indicating much-needed treatment improvement [<xref ref-type="bibr" rid="CR1">1</xref>]. Lung cancer is categorised based on histological categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Around 80&#8211;85% of lung cancers are NSCLC, divided mainly into adenocarcinoma (40&#8211;45%) of the small airway epithelium and type II alveolar cells, squamous cell lung carcinoma (25&#8211;30%) of the epithelial cells of the bronchial tubes and large cell carcinoma (5&#8211;10%) targeting the central parts of the lungs [<xref ref-type="bibr" rid="CR2">2</xref>].
</p><p id="Par3">The type of treatment for NSCLC depends on the tumour stage. In the treatment of stage I&#8211;III NSCLC, surgery is preferred and often combined with (neo)-adjuvant treatment using classic cytotoxic agents, immune checkpoint inhibitors, or targeted therapy [<xref ref-type="bibr" rid="CR3">3</xref>]. Treatment of stage IV NSCLC is based on patient and tumour characteristics such as performance score (i.e., Eastern Cooperative Oncology Group [ECOG] &#8211; performance score), molecular profiling of the tumour, and immunohistochemistry (i.e., Programmed Death Ligand 1 [PD-L1] expression). Its treatment includes targeted therapy, immunotherapy, and chemotherapy [<xref ref-type="bibr" rid="CR4">4</xref>]. However, while recent developments in targeted therapy have shown promising results in specific patient populations, classical cytotoxic therapy will remain an important pillar of the treatment of stage IV NSCLC for the coming decade.</p><p id="Par4">For cytotoxic drugs, there is always a complex balance between subtherapeutic therapy (i.e., under-exposure) and toxicity (i.e., over-exposure) to find the individual optimal therapeutic effective dose. Since systemic exposure to the drug largely determines its effect and toxicity, prediction of individual pharmacokinetics (PK) can be used to tailor the dose. Historically, the dosing of cytotoxic drugs has been adapted to body size, for example, by using the estimated body surface area (BSA). This approach is based on early studies by Pinkel (1958) and Freireich (1966) showing a &#8220;reasonable&#8221; relationship between BSA and the pharmacokinetics of various chemotherapeutic drugs [<xref ref-type="bibr" rid="CR5">5</xref>]. However, since body size only modestly correlates with the metabolic capacity of the liver and the glomerular filtration rate&#8212;the two main organ systems responsible for drug elimination&#8212;BSA is a poor predictor for individual pharmacokinetics [<xref ref-type="bibr" rid="CR6">6</xref>]. Moreover, using BSA for dosing is only based on correlation (which disappears in the pharmacokinetic interindividual variability) and not on a causal physiological relationship with the clearance of cytotoxic drugs [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par5">Nonetheless, the current dosing of cytotoxic agents for NSCLC treatment is still primarily BSA-based. This may lead to unwanted interindividual variability, as two patients with the same BSA may experience different drug exposures (and consequently, different treatment responses) due to variances in individual patient characteristics, such as hepatic or renal function, age, and genetic polymorphisms. High interindividual variability in clearance and exposure for many anticancer drugs has been observed, showing that dosing based on BSA leads to over- or under-exposure for the individual patient [<xref ref-type="bibr" rid="CR7">7</xref>]. Over-exposure is unwanted since it may lead to severe toxicity, early treatment discontinuation, and reduced quality of life. Under-exposure is unwanted since it may negatively impact the efficacy of anticancer treatment. Precision dosing is adjusting the dose based on the patient&#8217;s characteristics already known before the start of treatment (e.g., hepatic and renal function, genetic factors) or during treatment through assessment of the drug&#8217;s exposure, i.e., pharmacokinetically guided dosing using therapeutic drug monitoring (TDM)-guided or toxicity-guided dosing [<xref ref-type="bibr" rid="CR8">8</xref>]. In the era of advancing precision medicine, the tailoring of dosing of classical cytotoxic drugs to individual patients' characteristics is lagging and remains insufficient [<xref ref-type="bibr" rid="CR8">8</xref>]. Regulatory agencies, such as the Food and Drug Administration (FDA), have also realised that the current paradigm for the dose selection of new oncology drugs is inadequate and needs improvement [<xref ref-type="bibr" rid="CR9">9</xref>]. Through project Optimus, the FDA aims for a paradigm shift to identify optimal doses of new oncology drugs [<xref ref-type="bibr" rid="CR10">10</xref>]. However, this initiative does not extend to older oncology drugs, which remain largely unexamined under the current shifting framework, creating a significant knowledge gap. We postulate that existing oncological drugs, especially classical cytotoxic drugs, should not be neglected and should undergo the same re-evaluation to optimise their dosing strategies. As the population of patients with NSCLC is large, an even slight improvement in dosing can affect and improve the treatment of many patients. Therefore, the aim of this narrative review is to describe opportunities for precision dosing of classical cytotoxic drugs for improved safety and efficacy of chemotherapeutic treatment of NSCLC.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par6">The scope of this narrative review was limited to the treatment of NSCLC with classical cytotoxic agents, including platinum (cis- or carboplatin) and taxane (docetaxel, paclitaxel, or nab-paclitaxel) compounds, pemetrexed, gemcitabine, and vinorelbine [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. First, we assessed the European Public Assessments Reports (EPARs) from the European Medicines Agency (EMA) and pharmacology and PK reviews of the FDA gather regulatory insights on approved indications, dosing recommendations, and available pharmacokinetic/pharmacodynamic (PK/PD) data. From these regulatory documents, we extracted relevant information on each drug. Next, we examined the PK, PD, exposure-response relationships, and dose-treatment optimisation strategies for each cytotoxic agent. After that, we queried PubMed to identify additional relevant literature on personalised medicine of these cytotoxic agents. For example, when a PK relationship was found between BSA and exposure for a specific agent, we searched for &#8220;BSA&#8221; AND &#8220;exposure&#8221; AND &#8220;[drug-name]&#8221; (e.g., cisplatin, carboplatin). Filters were applied to include only English-language publications, with a priority given to studies in NSCLC populations, clinical trials, meta-analyses, and reviews, in that order. Lastly, we employed citation snowballing, specifically backward snowballing, by examining the reference lists of key studies to identify other potentially relevant publications.</p><p id="Par7">The general approach for dose individualisation of selected cytotoxic agents starts with the current state of dosing and general PK and PD characteristics (&#8220;PKs, PDs and current practice in dosing&#8221;), followed by &#8220;Promising developments&#8221; of opportunities and research already performed for optimising and personalising of dosing, followed by our recommendation to improve precision dosing of these cytotoxic agents. All directly implementable opportunities and proposed PK/PD relationships of these cytotoxic agents in treating NSCLC were summarised in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics, proposed PK/PD relationships and opportunities for precision dosing strategies for classical cytotoxic drugs in treatment of NSCLC</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Cytotoxic drug</th><th align="left" rowspan="2" colspan="1">Target</th><th align="left" rowspan="2" colspan="1">Approved dose</th><th align="left" colspan="2" rowspan="1">Proposed PK/PD relationships</th><th align="left" colspan="2" rowspan="1">Precision dosing</th></tr><tr><th align="left" colspan="1" rowspan="1">Efficacy</th><th align="left" colspan="1" rowspan="1">Toxicity</th><th align="left" colspan="1" rowspan="1">Opportunities for treatment optimisation to be directly implemented</th><th align="left" colspan="1" rowspan="1">Promising developments</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Cisplatin</td><td align="left" rowspan="2" colspan="1">Bind to DNA-adducts in cells</td><td align="left" colspan="1" rowspan="1">75 mg/m<sup>2</sup> IV Q3W</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1"><p>AUC</p><p><italic toggle="yes">C</italic><sub>max</sub></p></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"><p>Dosing based on renal function<sup>a</sup></p><p>Neutrophil-guided dosing<sup>a</sup></p><p>TDM-guided dosing in paediatric patients and 5-day continuous infusion<sup>b</sup></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Carboplatin</td><td align="left" colspan="1" rowspan="1"><p>400 mg/m<sup>2</sup> IV Q3W</p><p>Dose&#160;=&#160;AUC<sub>target</sub> * (GFR +25)</p></td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1"><p>Dosing based on cystatin C as novel biomarker for estimating carboplatin clearance</p><p>For example Schmitt et al<italic toggle="yes">.</italic> carboplatin clearance&#160;=&#160;117.8*(Cr<sub>serum</sub>/75)<sup>&#8722;&#160;0.450</sup> *cystatin C<sup>&#8722;&#160;0.385</sup>*(body weight/65)<sup>+&#160;0.504</sup>* (age/56)<sup>&#8722;&#160;0.366</sup>* 0.847<sup>sex</sup> with sex&#160;=&#160;0 for male [<xref ref-type="bibr" rid="CR58">58</xref>]</p></td><td align="left" colspan="1" rowspan="1"><p>TDM-guided dosing in paediatric and high-dose carboplatin protocols</p><p>Improved estimation of carboplatin clearance using:</p><p>&#160;1. CT derived body composition and serum creatinine<sup>a</sup></p><p>&#160;2. Pro-enkephalin</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Pemetrexed</td><td align="left" colspan="1" rowspan="1">Folate antimetabolite needed for DNA and RNA synthesis</td><td align="left" colspan="1" rowspan="1">500 mg/m<sup>2</sup> IV Q3W</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1"><p>AUC</p><p>Time above threshold</p></td><td align="left" colspan="1" rowspan="1">Dose individualization (for patients with CrCL &#8805; 45 mL/min) based on renal function to target an AUC of 164 mg/L*h</td><td align="left" colspan="1" rowspan="1"><p>TDM-guided dosing for normal renal function based on proposed target AUC of 164 mg/L*h [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]<sup>a</sup></p><p>Dosing adjustment in patients with impaired renal function (&lt;&#160;45&#160;mL/min) and potentially adding folinic acid prophylaxis therapy<sup>a</sup></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Docetaxel</td><td align="left" rowspan="3" colspan="1">Binding site GTP on microtubules</td><td align="left" colspan="1" rowspan="1">75 mg/m<sup>2</sup> IV Q3W</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1">AUC</td><td align="left" colspan="1" rowspan="1">Weekly dosing</td><td align="left" colspan="1" rowspan="1"><p>Neutrophil-guided dosing<sup>a</sup></p><p>TDM-guided dosing in specific populations such as patients with mCRPC</p><p>&#160;Genotyping and metabolic phenotyping (e.g., <italic toggle="yes">CYP3A</italic> and <italic toggle="yes">ABCB1</italic>)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">175 mg/m<sup>2</sup> IV Q3W</td><td align="left" rowspan="2" colspan="1">Time above threshold</td><td align="left" rowspan="2" colspan="1">Time above threshold</td><td align="left" colspan="1" rowspan="1"><p>TDM-guided dosing at time-above-threshold of 0.05 &#956;mol/L (T<sub>&gt;0.05</sub>)</p><p>Weekly dosing</p></td><td align="left" colspan="1" rowspan="1">Genotyping and metabolic phenotyping (e.g., <italic toggle="yes">CYP2C8*3</italic> and<italic toggle="yes"> ABCB1)</italic></td></tr><tr><td align="left" colspan="1" rowspan="1">Nab-paclitaxel</td><td align="left" colspan="1" rowspan="1">100 mg/m<sup>2</sup> IV Q1W</td><td align="left" colspan="1" rowspan="1">Weekly dosing</td><td align="left" colspan="1" rowspan="1"><p>Neutrophil-guided dosing<sup>b</sup></p><p>TDM-guided dosing</p><p>Genotyping and metabolic phenotyping (e.g., <italic toggle="yes">CYP2C8*3</italic> and<italic toggle="yes"> ABCB1)</italic></p></td></tr><tr><td align="left" colspan="1" rowspan="1">Gemcitabine</td><td align="left" colspan="1" rowspan="1">Pyrimidine antagonist</td><td align="left" colspan="1" rowspan="1">1250 mg/m<sup>2</sup> IV Q3W</td><td align="left" colspan="2" rowspan="1">Inconclusive</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"><p>Prolonged infusion times</p><p>Genotyping (e.g., <italic toggle="yes">dCK</italic> and <italic toggle="yes">hENT</italic><sup>a,b</sup>)</p><p>Neutrophil-guided dosing</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Vinorelbine</td><td align="left" colspan="1" rowspan="1">Binding site &#946;-tubulin on microtubules</td><td align="left" colspan="1" rowspan="1"><p>25&#8211;30 mg/m<sup>2</sup> IV</p><p>60 mg/m<sup>2</sup> PO</p></td><td align="left" colspan="2" rowspan="1">Inconclusive</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Neutrophil-guided dosing<sup>a</sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">AUC</italic> area under the curve, <italic toggle="yes">CrCL</italic> creatinine clearance, <italic toggle="yes">C</italic><sub><italic toggle="yes">max</italic></sub> maximum concentration, <italic toggle="yes">dCK</italic> deoxycytidine kinase, <italic toggle="yes">GFR</italic> glomerular filtration rate, <italic toggle="yes">hENT</italic> human equilibrative nucleoside transporters, <italic toggle="yes">IV</italic> intravenously, <italic toggle="yes">PK/PD</italic> pharmacokinetic/pharmacodynamic, <italic toggle="yes">PO</italic> per os (by mouth), mCRPC metastatic castration-resistant prostate cancer, <italic toggle="yes">NSCLC</italic> non-small cell lung cancer, <italic toggle="yes">Q1W</italic> weekly dosing, <italic toggle="yes">Q3W</italic> 3-weekly dosing, <italic toggle="yes">TDM</italic> therapeutic drug monitoring</p><p><sup>a</sup>No prospective studies available</p><p><sup>b</sup>Not investigated in NSCLC population</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec3"><title>Platinum-Based Compounds (Cisplatin, Carboplatin)</title><p id="Par8">After intravenous administration, cis- and carboplatin are hydrolysed to active platinum metabolites, which bind to proteins through sulfide bonds of albumin and globulins. Hence, only a small part of elimination depends on protein turnover [<xref ref-type="bibr" rid="CR11">11</xref>]. Compared to cisplatin, carboplatin is chemically more stable and less reactive, hydrolysed&#160;at a lower constant rate, and forms fewer complexes with plasma proteins. Both cisplatin and carboplatin are cleared by the kidneys as free platinum, with carboplatin being excreted up to 65&#8211;77% within 24 hours versus 28% for cisplatin [<xref ref-type="bibr" rid="CR11">11</xref>]. Hence, the dosing of carboplatin is adjusted for renal function, while adjustment of the dosing of cisplatin in patients with renal impairment is only advised [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par9">Both drugs are considered interchangeable for the treatment of NSCLC, as a large meta-analysis (<italic toggle="yes">n</italic>&#160;=&#160;2048) including 12 randomised controlled trials (RCTs) showed no significant differences in survival outcomes between first-line cisplatin- and carboplatin-based chemotherapy. Nevertheless, differences in toxicity profiles exist, with a higher incidence of thrombocytopenia and anaemia for carboplatin and an increased risk of nausea and vomiting for cisplatin [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, cisplatin shows higher incidences of ototoxicity and neurotoxicity compared to carboplatin. The specific mechanism underlying this difference in sensitivity is still poorly understood. However, studies have found a higher accumulation of cisplatin in the cochlea, resulting in reactive oxygen species (ROS) overload and an impaired antioxidant system [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par10">The cytotoxic mode of action of platinum drugs has been linked to forming DNA-crosslinks, causing DNA damage, and inducing apoptosis of tumour cells, but as a side effect also in healthy cells [<xref ref-type="bibr" rid="CR11">11</xref>]. Most chemotherapy-induced toxicity encompasses rapidly dividing cells, including in the bone marrow. Neutropenia is the most common form of bone marrow toxicity, as neutrophils are especially vulnerable to cell-diving toxicity due to their extremely short circulating half-life (6&#8211;8&#160;h) and the need for continuous replenishment by the bone marrow [<xref ref-type="bibr" rid="CR15">15</xref>]. The nadir neutrophil count occurs 8&#8211;10&#160;days after administration and is associated with, among others, systemic exposure to the specific cytotoxic drug [<xref ref-type="bibr" rid="CR16">16</xref>]. An exception to this rule is carboplatin, where carboplatin-associated haematological toxicity mainly manifests as thrombocytopenia. This difference in haematological toxicity might be explained by the downregulation of the JAK2/STAT2 pathway critical for megakaryocyte proliferation and differentiation by carboplatin [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par11">Platinum-based drugs not only function as cytotoxic drugs but may also exert immunomodulatory effects that contribute to their efficacy and synergetic effect in chemoimmunotherapy. For example, cisplatin in vitro increases the number of effector cells (i.e., natural killer [NK] cells, cytotoxic T-cells, antigen presenting cells [APCs], and macrophages) while decreasing the number of myeloid-derived suppressor cells (MDSCs) and regulatory T-cells [<xref ref-type="bibr" rid="CR18">18</xref>]. Moreover, cisplatin seems to enhance the effect of immunotherapy by remodelling the tumour microenvironment (by ferroptosis and neutrophil polarisation) and enhancing T-cell infiltration and Th1 differentiation [<xref ref-type="bibr" rid="CR19">19</xref>]. The same synergistic effect was found for carboplatin and PD-1 inhibitors (i.e., pembrolizumab and nivolumab) in NSCLC cell lines [<xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec4"><title>Cisplatin</title><sec id="Sec5"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par12">Cisplatin entered the market in 1978 as an anticancer drug for the first-line treatment of several malignant tumours, including lung, ovarian, and colorectal cancers [<xref ref-type="bibr" rid="CR21">21</xref>]. The cumulative exposure to unbound cisplatin (expressed as area under the curve [AUC]) is strongly correlated with the formation of DNA-adducts in tumour cells and tumour response [<xref ref-type="bibr" rid="CR22">22</xref>] as well as toxicity [<xref ref-type="bibr" rid="CR23">23</xref>]. The main cisplatin-induced toxicities are nephrotoxicity, ototoxicity, myelotoxicity, nausea, and peripheral neuropathy [<xref ref-type="bibr" rid="CR23">23</xref>]. Specifically, an increased systemic drug exposure (AUC) and maximal plasma concentration (<italic toggle="yes">C</italic><sub>max</sub>) of unbound platinum are correlated with an increased risk of cisplatin-induced nephrotoxicity [<xref ref-type="bibr" rid="CR24">24</xref>]. Slow infusion rates may prevent nephrotoxicity and myelotoxicity in addition to hyperhydration and diuresis [<xref ref-type="bibr" rid="CR25">25</xref>]. Incidences of neuropathy and ototoxicity are only preventable by dose reduction or cessation of cisplatin [<xref ref-type="bibr" rid="CR26">26</xref>]. Although BSA only weakly correlates&#160;with cisplatin systemic exposure [<xref ref-type="bibr" rid="CR27">27</xref>], cisplatin is still dosed based on BSA 75&#8211;100&#160;mg/m<sup>2</sup> every three weeks (Q3W) in NSCLC treatment [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec6"><title>Promising Developments</title><p id="Par13">Since cisplatin is eliminated by the kidneys, dosing in patients with renal impairment should be adjusted. At the moment, dose adjustment in patients with impaired renal function is only advised by the label and not mandatory [<xref ref-type="bibr" rid="CR12">12</xref>]. However, recent guidelines, including the International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD), recommend avoiding the administration of cisplatin in patients with renal impairment (estimated glomerular filtration rate [eGFR] &lt;&#160;45&#160;mL/min/1.73&#160;m<sup>2</sup>) and exercising extra caution in those with an eGFR of 45&#8211;59&#160;mL/min/1.73&#160;m<sup>2</sup> [<xref ref-type="bibr" rid="CR28">28</xref>]. Limited prospective data in NSCLC are available, and the best approach for adjusting cisplatin dosage in patients with impaired renal function has yet to be determined [<xref ref-type="bibr" rid="CR29">29</xref>]. Interestingly enough, a study investigating dose reduction of cisplatin for patients (<italic toggle="yes">n</italic>&#160;=&#160;151) with metastatic urothelial carcinoma and renal dysfunction, 30&#8211;60&#160;mL/min found no negative impact or significant differences in severe toxicity or survival outcomes compared to standard dosing in patients with renal function &gt;&#160;60&#160;mL/min [<xref ref-type="bibr" rid="CR30">30</xref>]. Since cisplatin and carboplatin are considered interchangeable in treating NSCLC [<xref ref-type="bibr" rid="CR13">13</xref>], changing treatment to carboplatin may also be an option to adjust treatment to individual renal function more easily (see chapter Carboplatin).</p><p id="Par14">An increasing number of pharmacogenomic studies of cisplatin-induced toxicity have been published, especially regarding cisplatin-induced ototoxicity [<xref ref-type="bibr" rid="CR31">31</xref>] and nephrotoxicity [<xref ref-type="bibr" rid="CR32">32</xref>]. For example, a large genome-wide study (GWAS) of 608 European patients found an association between a predisposition of the <italic toggle="yes">BACH2</italic> gene and an increased risk of cisplatin-induced nephrotoxicity [<xref ref-type="bibr" rid="CR33">33</xref>]. At the moment, there is no place for PGx for cisplatin-induced toxicity due to the lack of consistency in study results. Nevertheless, pharmacogenomics remains highly relevant and important for future research.</p><p id="Par15">Neutrophil-guided dosing of cisplatin could be a potential opportunity for treatment optimisation. A large retrospective study by Di Maio et al based on three RCTs (<italic toggle="yes">n</italic>&#160;=&#160;1265) found the degree of cisplatin-induced neutropenia to be associated with increased overall survival (OS) [<xref ref-type="bibr" rid="CR34">34</xref>]. Unfortunately, to our knowledge, no prospective studies have confirmed this relationship between the incidence of neutropenia and survival outcomes in cisplatin treatment.</p><p id="Par16">As cisplatin exposure is related to its efficacy and toxicity, TDM-guided dosing of cisplatin based on reaching a specific AUC or <italic toggle="yes">C</italic><sub>max</sub> would be possible, especially in specific populations (e.g., paediatric, high-dose treatment) and for treatment that is administered over several days [<xref ref-type="bibr" rid="CR35">35</xref>]. To date, no studies have investigated the added value of TDM-guided dosing of cisplatin in NSCLC patients. In patients with other types of solid tumours, TDM-guided dosing of cisplatin (<italic toggle="yes">n</italic>&#160;=&#160;58) as a 5-day continuous infusion successfully reached the target <italic toggle="yes">C</italic><sub>max</sub> and reduced interindividual variability of PK parameters [<xref ref-type="bibr" rid="CR36">36</xref>]. Another PK study in 19 patients with different solid tumours also successfully achieved targeted <italic toggle="yes">C</italic><sub>max</sub>, with little grade III&#8211;IV toxicities (10% leukocytopenia, 6% anaemia, and thrombocytopenia) and no nephrotoxicity and neurotoxicity, and all patients are still alive and disease-free after a follow-up of 15&#160;years [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec7"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par17">Currently, dosing is still based on BSA, and there is insufficient evidence to adjust cisplatin dosing based on renal function or to use cisplatin-induced haematological toxicity, a potential opportunity for neutrophil-guided dosing. For specific NSCLC patient populations like paediatric patients or 5-day continuous infusion of cisplatin, we recommend further exploring TDM-guided dosing based on the limited promising results in other tumours.</p></sec></sec><sec id="Sec8"><title>Carboplatin</title><sec id="Sec9"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par18">Carboplatin entered the market roughly ten years after cisplatin in 1986 as a potential substitution for cisplatin [<xref ref-type="bibr" rid="CR38">38</xref>]. Carboplatin was initially approved on BSA-based dosing [<xref ref-type="bibr" rid="CR39">39</xref>]. However, studies showed carboplatin clearance to be linearly correlated with glomerular filtration rate (GFR) [<xref ref-type="bibr" rid="CR40">40</xref>]. The toxicity of carboplatin treatment showed high variability and higher incidences of (haematological) toxicity with decreasing renal function [<xref ref-type="bibr" rid="CR41">41</xref>]. Since carboplatin systemic drug exposure correlates well with toxicity, Calvert et al developed the following dosing formula for dosing based on AUC: Dose (mg)&#160;=&#160;AUC<sub>target</sub> * (GFR +&#160;25) [<xref ref-type="bibr" rid="CR40">40</xref>]. In this formula, the GFR is based on the measured GFR using chromium 51-ethylenediaminetetra-acetic acid (<sup>51</sup>Cr-EDTA). In daily practice, directly measuring the GFR using exogenous markers is complex, expensive, and inconvenient [<xref ref-type="bibr" rid="CR42">42</xref>], and the GFR is frequently substituted by the estimated creatine clearance (CrCL) [<xref ref-type="bibr" rid="CR43">43</xref>]. However, creatinine is not 100% cleared by the glomerulus but also undergoes active tubular secretion, resulting in a 10&#8211;20% systematic overestimation of GFR [<xref ref-type="bibr" rid="CR42">42</xref>]. Moreover, besides biased estimation, serum creatinine-based estimations of renal function have proven to be imprecise. A study by Ekhart et al showed that adjusting carboplatin dose using estimated renal function based on serum creatinine provided similar drug exposure levels as administering a flat dose to patients with normal renal function [<xref ref-type="bibr" rid="CR44">44</xref>]. This finding can be explained by the fact that serum creatinine correlates with muscle mass and that in advanced cancer patients, muscle mass deviates from the population where equations for estimation of renal function were developed [<xref ref-type="bibr" rid="CR45">45</xref>]. For example, cachectic patients, often seen in oncological populations, have an abnormally low creatinine production, and assessing the creatinine clearance in this population will provide an overestimation of GFR [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Directly measuring (24-hour) creatinine clearance as a proxy for GFR might be more accurate than relying on estimated GFR for carboplatin dosing. Still, this has been proved inaccurate for carboplatin dose individualisation [<xref ref-type="bibr" rid="CR48">48</xref>].</p></sec><sec id="Sec10"><title>Promising Developments</title><p id="Par19">Since carboplatin is dosed to a specific target AUC, TDM-guided dosing may aid in dosing carboplatin to improve target attainment. An extensive review by Maillard et al [<xref ref-type="bibr" rid="CR35">35</xref>] found multiple small studies demonstrating that TDM-guided carboplatin dosing in children with retinoblastoma successfully achieved target AUC, leading to remission without reported renal toxicity [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Similarly, high-dose carboplatin has been shown to reach target AUC in adults with advanced germ cell tumours [<xref ref-type="bibr" rid="CR51">51</xref>]. Looking at carboplatin toxicity and treatment outcomes, the association between (haematological) toxicity and survival outcomes of carboplatin treatment has not been established [<xref ref-type="bibr" rid="CR52">52</xref>]. However, there is still potential for improvement in carboplatin dosing by adjusting for baseline haematological status (i.e., low platelets or absolute neutrophil counts at baseline), concomitant therapy, and better estimation of renal function [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par20">As stated earlier, estimating renal function based on the creatinine clearance (i.e., carboplatin clearance) in patients with an abnormal body composition gives an under- or over-estimation of the eGFR. However, developments in deep learning and medical imaging allow accurate assessment of an individual&#8217;s body composition, including muscle mass, using X-ray computed tomography (CT) scans [<xref ref-type="bibr" rid="CR54">54</xref>]. As muscle mass correlates with creatinine production, creatinine clearance might be accurately estimated using a CT-scan assessment of body composition and serum creatinine to improve carboplatin dosing [<xref ref-type="bibr" rid="CR55">55</xref>]. Other biomarkers, cystatin C and pro-enkephalin (PENK), are more effective in estimating the GFR than creatinine clearance [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Using cystatin C for dosing of carboplatin better attains target AUC compared to serum creatinine-based assessments of renal function in individualising the dose [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. White-Koning et al combined three previously published clinical studies of 491 patients receiving carboplatin and compared various formulas for estimating carboplatin clearance to actual clearance. They found that cystatin C (used in the CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration]) was the best predictor (i.e., least bias, highest precision) of carboplatin clearance, independent of other patient characteristics such as sex, body mass index (BMI) (only significant at the 1% level), and age [<xref ref-type="bibr" rid="CR60">60</xref>]. See Table <xref rid="Tab2" ref-type="table">2</xref> for different cystatin C formulae tested for estimating carboplatin clearance.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Different cystatin C formulas for estimating carboplatin clearance</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">Schmitt et al [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left" colspan="2" rowspan="1"><inline-formula id="IEq1"><alternatives><tex-math id="d33e927">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{CL }[\text{mL}/\text{min}]=117.8*{\left(\frac{{\text{Cr}}_{\text{SERUM}}}{75}\right)}^{-0.450}*{\left(\frac{{\text{cystatin C}}_{\text{SERUM}}}{1.0}\right)}^{-0.385}*{\left(\frac{\text{WEIGHT}}{65}\right)}^{+0.504}*{\left(\frac{\text{AGE}}{56}\right)}^{-0.366}*0.847\, [\text{IF FEMALE}]$$\end{document}</tex-math><mml:math id="d33e932"><mml:mrow><mml:mtext>CL</mml:mtext><mml:mspace width="0.333333em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>mL</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>min</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>117.8</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mtext>Cr</mml:mtext><mml:mtext>SERUM</mml:mtext></mml:msub><mml:mn>75</mml:mn></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>0.450</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mrow><mml:mtext>cystatin C</mml:mtext></mml:mrow><mml:mtext>SERUM</mml:mtext></mml:msub><mml:mrow><mml:mn>1.0</mml:mn></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>0.385</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:mtext>WEIGHT</mml:mtext><mml:mn>65</mml:mn></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>+</mml:mo><mml:mn>0.504</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:mtext>AGE</mml:mtext><mml:mn>56</mml:mn></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>0.366</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mn>0.847</mml:mn><mml:mspace width="0.166667em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>IF FEMALE</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1492_Article_IEq1.gif"/></alternatives></inline-formula></td></tr><tr><td align="left" colspan="1" rowspan="1">Thomas et al [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left" colspan="2" rowspan="1"><inline-formula id="IEq2"><alternatives><tex-math id="d33e1018">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{CL }[\text{mL}/\text{min}]=110.0*{\left(\frac{{\text{Cr}}_{\text{SERUM}}}{75}\right)}^{-0.512}*{\left(\frac{{\text{cystatin C}}_{\text{SERUM}}}{1.0}\right)}^{-0.327}*{\left(\frac{\text{WEIGHT}}{65}\right)}^{+0.474}*{\left(\frac{\text{AGE}}{56}\right)}^{-0.387}*0.854\, [\text{IF FEMALE}]$$\end{document}</tex-math><mml:math id="d33e1023"><mml:mrow><mml:mtext>CL</mml:mtext><mml:mspace width="0.333333em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>mL</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>min</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>110.0</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mtext>Cr</mml:mtext><mml:mtext>SERUM</mml:mtext></mml:msub><mml:mn>75</mml:mn></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>0.512</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mrow><mml:mtext>cystatin C</mml:mtext></mml:mrow><mml:mtext>SERUM</mml:mtext></mml:msub><mml:mrow><mml:mn>1.0</mml:mn></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>0.327</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:mtext>WEIGHT</mml:mtext><mml:mn>65</mml:mn></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>+</mml:mo><mml:mn>0.474</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:mtext>AGE</mml:mtext><mml:mn>56</mml:mn></mml:mfrac></mml:mfenced></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>0.387</mml:mn></mml:mrow></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mn>0.854</mml:mn><mml:mspace width="0.166667em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>IF FEMALE</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1492_Article_IEq2.gif"/></alternatives></inline-formula></td></tr><tr><td align="left" rowspan="2" colspan="1">CKD-EPI (creatinine + cystatin C) [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left" colspan="2" rowspan="1"><inline-formula id="IEq3"><alternatives><tex-math id="d33e1109">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\text{eGFR }[\text{mL}/\text{min}/1.73 \,{\text{m}}^{2}]=135*{\left(\frac{{\text{Cr}}_{\text{SERUM}}}{\text{A}}\right)}^{\text{B}}*{\left(\frac{{\text{cystatin C}}_{\text{SERUM}}}{\text{C}}\right)}^{\text{D}}*{0.9961}^{\text{AGE}}*0.963\, [\text{IF FEMALE}]$$\end{document}</tex-math><mml:math id="d33e1114"><mml:mrow><mml:mtext>eGFR</mml:mtext><mml:mspace width="0.333333em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>mL</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>min</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mn>1.73</mml:mn><mml:mspace width="0.166667em"/><mml:msup><mml:mrow><mml:mtext>m</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>135</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mtext>Cr</mml:mtext><mml:mtext>SERUM</mml:mtext></mml:msub><mml:mtext>A</mml:mtext></mml:mfrac></mml:mfenced></mml:mrow><mml:mtext>B</mml:mtext></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mfenced close=")" open="("><mml:mfrac><mml:msub><mml:mrow><mml:mtext>cystatin C</mml:mtext></mml:mrow><mml:mtext>SERUM</mml:mtext></mml:msub><mml:mtext>C</mml:mtext></mml:mfrac></mml:mfenced></mml:mrow><mml:mtext>D</mml:mtext></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:msup><mml:mrow><mml:mn>0.9961</mml:mn></mml:mrow><mml:mtext>AGE</mml:mtext></mml:msup><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mn>0.963</mml:mn><mml:mspace width="0.166667em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mtext>IF FEMALE</mml:mtext><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1492_Article_IEq3.gif"/></alternatives></inline-formula></td></tr><tr><td align="left" colspan="1" rowspan="1"><p>If <italic toggle="yes">male</italic> and:</p><p>&#160;Serum creatinine &#8804; 0.9 and serum cystatin C &#8804; 0.8:</p><p>A&#160;=&#160;0.9, B&#160;=&#160;&#8722;0.144, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.323</p><p>&#160;Serum creatinine &#8804; 0.9 and serum cystatin C &gt; 0.8:</p><p>A&#160;=&#160;0.9, B&#160;=&#160;&#8722;0.144, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.778</p><p>&#160;Serum creatinine &gt; 0.9 and serum cystatin C &#8804; 0.8:</p><p>A&#160;=&#160;0.9, B&#160;=&#160;&#8722;0.544, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.323</p><p>&#160;Serum creatinine &gt; 0.9 and serum cystatin C &gt; 0.8:</p><p>A&#160;=&#160;0.9, B&#160;=&#160;&#8722;0.544, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.778</p></td><td align="left" colspan="1" rowspan="1"><p>If <italic toggle="yes">female</italic> and:</p><p>&#160;Serum creatinine &#8804; 0.7 and serum cystatin C &#8804; 0.8:</p><p>A&#160;=&#160;0.7, B&#160;=&#160;&#8722;0.219, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.323</p><p>&#160;Serum creatinine &#8804; 0.7 and serum cystatin C &gt; 0.8:</p><p>A&#160;=&#160;0.7, B&#160;=&#160;&#8722;0.219, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.778</p><p>&#160;Serum creatinine &gt; 0.7 and serum cystatin C &#8804; 0.8:</p><p>A&#160;=&#160;0.7, B&#160;=&#160;&#8722;0.544, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.323</p><p>&#160;Serum creatinine &gt; 0.7 and serum cystatin C &gt; 0.8:</p><p>A&#160;=&#160;0.7, B&#160;=&#160;&#8722;0.544, C&#160;=&#160;0.8, and D&#160;=&#160;&#8722;0.778</p></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec11"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par21">Dosing of carboplatin is already adjusted for exposure (AUC) and clearance (GFR) using the Calvert formula. We recommend implementing and using cystatin C as a marker for renal clearance and adjusting dosage for baseline haematological status and concomitant therapy. Cystatin C has the most evidence as an ideal estimator of carboplatin clearance independent of patient characteristics (see Table <xref rid="Tab1" ref-type="table">1</xref>). Moreover, prospective studies in cystatin C have already shown that it is a better approximation of carboplatin clearance compared to conventional creatinine clearance formulae. However, its impact on clinical outcomes has yet to be evaluated. Finally, TDM-guided dosing could be an option in specific patient groups, such as paediatrics or high-dose protocols.</p></sec></sec><sec id="Sec12"><title>Pemetrexed</title><sec id="Sec13"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par22">Pemetrexed is a folate antimetabolite, moderately protein bound (81%), and is almost entirely eliminated as unchanged drug by the kidneys (70&#8211;90% within 24&#160;h in patients with adequate renal function) [<xref ref-type="bibr" rid="CR61">61</xref>]. After uptake in the (tumour) cell, a polyglutamate chain is added by folylpolyglutamate synthetase (FPGS) increasing the affinity and inhibition by pemetrexed of enzymes used in purine and pyrimidine synthesis, including thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyl transferase (GARFT). Inhibiting these enzymes disrupts DNA and RNA synthesis, thus blocking cell replications and growth [<xref ref-type="bibr" rid="CR62">62</xref>]. Thymidylate synthase inhibition and consequential cell death of tumour and healthy cells are the most important factors for both the efficacy and toxicity effects of pemetrexed (mainly nephrotoxicity and haematological toxicity) [<xref ref-type="bibr" rid="CR62">62</xref>]. Furthermore, pemetrexed acts synergetically when combined with immunotherapy. By inactivating TS in tumour cells, pemetrexed stimulates the upregulation of PD-L1 by activating <italic toggle="yes">CD274</italic> through upregulating NF-&#954;B signalling [<xref ref-type="bibr" rid="CR63">63</xref>], and the addition of pemetrexed to platinum-pembrolizumab doublet chemotherapy significantly improves OS in patients with stage IV NSCLC [<xref ref-type="bibr" rid="CR64">64</xref>], as well as for platinum-atezolizumab [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par23">Since pemetrexed is mainly excreted by the kidneys by both tubular secretion and glomerular filtration, clearance of pemetrexed correlates linearly with renal function [<xref ref-type="bibr" rid="CR66">66</xref>]. Hence, a decrease in renal function will lead to an increase in pemetrexed exposure and risk of (haematological) toxicity [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Even though pemetrexed exposure primarily depends on renal function, dosing&#160;is individualised based&#160;on BSA, with an approved dose of 500 mg/m<sup>2</sup> every 3 weeks [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p id="Par24">The primary haematological toxicity for pemetrexed is neutropenia, as observed in early trials with a 39&#8211;42% incidence for grade III&#8211;IV neutropenia for pemetrexed monotherapy (500&#8211;600&#160;mg/m<sup>2</sup> without vitamin supplementation) [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. Pemetrexed-induced neutropenia is caused by the inhibition of proliferation of progenitor cells to fully differentiated leukocytes [<xref ref-type="bibr" rid="CR72">72</xref>] and follows the maturation and life cycle of neutrophils with the nadir absolute neutrophil count at 8&#8211;10&#160;days after administration [<xref ref-type="bibr" rid="CR69">69</xref>]. An extensive study by Niyikiza et al showed that vitamin B12 deficiency is associated with increased myelotoxicity [<xref ref-type="bibr" rid="CR73">73</xref>]. These findings resulted in adding folic acid (vitamin B9) and vitamin B12 as standard supplementation in pemetrexed treatment. After introducing vitamin supplementation, a Phase III study showed a decrease in haematological toxicity to 5.8% grade III&#8211;IV neutropenia and 1.9% febrile neutropenia [<xref ref-type="bibr" rid="CR74">74</xref>]. However, real-world data show a higher incidence of 26% for grade III&#8211;IV neutropenia [<xref ref-type="bibr" rid="CR75">75</xref>]. Haematological toxicity of pemetrexed is driven by a &#8220;time above a toxicity concentration threshold&#8221; [<xref ref-type="bibr" rid="CR76">76</xref>], comparable to methotrexate [<xref ref-type="bibr" rid="CR77">77</xref>]. Consequently, patients with decreased pemetrexed elimination (i.e., impaired renal function) are prone to haematological toxicity. Moreover, cumulative exposure to pemetrexed was found to be a risk factor for the development of renal injury, consequently associated with an increased incidence of treatment discontinuation related to renal events of 4% to 33% increasing with age, pre-existing condition, and use of nephrotoxic drugs [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. Hence, patients with impaired renal function (&lt;&#160;45&#160;mL/min) cannot be administered an effective dose without risk for severe toxicity [<xref ref-type="bibr" rid="CR80">80</xref>], and dosing in patients with renal function &lt;&#160;45&#160;mL/min is contraindicated [<xref ref-type="bibr" rid="CR69">69</xref>]. Other non-haematological toxicities for pemetrexed, besides nephrotoxicity, include gastro-intestinal and skin toxicities [<xref ref-type="bibr" rid="CR69">69</xref>]. Cells in the gastro-intestinal tracts and skin contain both highly proliferating cells and are therefore more prone to cytotoxic effects of pemetrexed. For skin toxicities, it is still unclear if these reactions are immunologically mediated or arise from the direct cytotoxic effect on keratinocytes [<xref ref-type="bibr" rid="CR81">81</xref>].</p></sec><sec id="Sec14"><title>Promising Developments</title><p id="Par25">For efficacy, higher dosing of pemetrexed up to 900 or 1000&#160;mg/m<sup>2</sup> every 3&#160;weeks did not improve survival outcomes compared to 500&#160;mg/m<sup>2</sup> dosing, but came with greater toxicity [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. While pemetrexed exposure largely depends on renal function, dosing based on BSA proves to be effective and generally safe in patients with adequate renal function (CrCL &#8805;&#160;45&#160;mL/min) [<xref ref-type="bibr" rid="CR84">84</xref>]. However, a recent study applying dose individualisation for pemetrexed based on renal function (dose&#160;=&#160;109&#160;&#215;&#160;[weight/70]<sup>0.75</sup>&#160;+&#160;561&#160;&#215;&#160;[eGFR/75]) showed the potential to reduce the incidence of toxicity (i.e., neutropenia) and decrease the costs of pemetrexed-associated neutropenia without compromising effective exposure [<xref ref-type="bibr" rid="CR85">85</xref>]. Recently, it was found that the CKD-EPI equation to estimate the GFR using serum creatinine and cystatin C could best predict the pemetrexed PKs, showing opportunities for better dose individualisation [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par26">Large interindividual variability in pemetrexed plasma concentration is observed, and TDM-guided dosing could be used to reduce variability in specific cases (e.g., high risk of toxicity, interaction with concomitant medication) [<xref ref-type="bibr" rid="CR87">87</xref>]. A proposed target AUC for effective and safe treatment has already been determined for pemetrexed at 164&#160;mg/L*h [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. However, the target AUC is not a reliable predictor of toxicity in patients with impaired renal function. Instead, time above the threshold concentration is a more accurate measure for predicting pemetrexed toxicity in these patients. Boosman et al identified pemetrexed threshold concentrations of 0.030&#160;mg/L for non-supplemented patients and 0.110 mg/L for vitamin-supplemented patients for daily dosing of pemetrexed [<xref ref-type="bibr" rid="CR76">76</xref>].</p><p id="Par27">Finally, the timing of pemetrexed administration may be an important factor in optimising pemetrexed efficacy, especially since NSCLC expresses various circadian genes that play key roles in DNA synthesis and nucleotide metabolism [<xref ref-type="bibr" rid="CR88">88</xref>]. A retrospective study in 78 advanced NSCLC patients showed that patients who received pemetrexed and platinum in the morning (<italic toggle="yes">n</italic>&#160;=&#160;26) had a higher PFS compared to patients receiving chemotherapy after 2 pm (<italic toggle="yes">n</italic>&#160;=&#160;52; 13 vs 43&#160;months, respectively) [<xref ref-type="bibr" rid="CR89">89</xref>].</p></sec><sec id="Sec15"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par28">For patients with adequate renal function (CrCL &#8805;&#160;45&#160;mL/min), dose individualisation based on renal function to target an AUC of 164&#160;mg/L*h could already be implemented in clinical practice, similar to carboplatin dosing based on target AUC. Preferably, the CKD-EPI equation using serum creatinine and cystatin C should be used. However, caution is warranted for patients with impaired renal function, as data in this population remain limited. We align with regulatory guidelines contra-indicating the administration of pemetrexed to patients with CrCL &lt;&#160;45 mL/min.</p></sec></sec><sec id="Sec16"><title>Taxanes (Docetaxel, Paclitaxel, Nab-Paclitaxel)</title><p id="Par29">Taxanes are plant isolates used as anticancer drugs for NSCLC. It started with the discovery of paclitaxel in 1971 from the yew tree: <italic toggle="yes">Taxus brevifolia</italic>. At that time, the direct extraction of the highly lipophilic paclitaxel from the <italic toggle="yes">Taxus brevifolia</italic> was not economically viable, needing at least 2&#8211;3 full-grown yew trees to treat one patient [<xref ref-type="bibr" rid="CR90">90</xref>]. Only 20&#160;years later, the preparation of economically viable quantities of paclitaxel was possible by a semisynthetic approach of modification of the precursor 10-deacetyl-baccatin III naturally and in high quantities available from the extraction of the needles of the European <italic toggle="yes">Taxus Baccata</italic>. From 1996 onwards, another semisynthetic derivative of 10-deacetyl-baccatin III was developed: docetaxel [<xref ref-type="bibr" rid="CR91">91</xref>].</p><p id="Par30">Both docetaxel and paclitaxel are highly lipophilic and extensively bound to plasma proteins [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. They are metabolised in the liver by cytochrome P450 (CYP) enzymes and excreted through the bile. Additionally, both drugs are substrates for ATP-binding cassette (ABC) transporters, which facilitate their efflux from cells, a process that affects treatment efficacy (e.g., tumour resistance due to the efflux of taxanes by cancer cells) and toxicity (e.g., reduced efflux of taxanes by healthy cells) [<xref ref-type="bibr" rid="CR91">91</xref>]. Solvents are added to their formulations to improve the solubility of docetaxel and paclitaxel. Docetaxel is made soluble by adding polysorbate 80 [<xref ref-type="bibr" rid="CR92">92</xref>]. Paclitaxel uses the micelle-forming cremophor EL to increase its water solubility [<xref ref-type="bibr" rid="CR93">93</xref>]. Both compounds are associated with high rates of hypersensitivity and infusion reactions and require the addition of prophylactic antihistamines and dexamethasone [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Moreover, polysorbate 80 and cremophor EL can hinder circulating taxane molecules from crossing the endothelial barrier of blood vessels or penetrating tumour tissue [<xref ref-type="bibr" rid="CR96">96</xref>]. To tackle these problems and reduce toxicity while increasing efficacy, nano-formulation of albumin-bound paclitaxel (nab-paclitaxel) was developed [<xref ref-type="bibr" rid="CR91">91</xref>]. A large Phase III trial compared docetaxel (60&#160;mg/m<sup>2</sup> Q3W) with nab-paclitaxel (100 mg/m<sup>2</sup> weekly) in 503 patients with advanced NSCLC and found no significant differences in OS (adjusted hazard ratio (aHR)&#160;=&#160;0.85 (95% confidence interval [CI]: 0.68&#8211;1.07). However, nab-paclitaxel showed an increased progression-free survival (PFS; aHR&#160;=&#160;0.76; 95% CI 0.63&#8211;0.92, <italic toggle="yes">p</italic>&#160;=&#160;0.0042) compared to docetaxel and a lower incidence of grade III&#8211;IV febrile neutropenia (2% vs 22%), although with a higher incidence of grade III&#8211;IV peripheral sensory neuropathy (10% vs 1%) [<xref ref-type="bibr" rid="CR97">97</xref>]. The same trend was seen in 1052 patients with advanced NSCLC treated with paclitaxel (200&#160;mg/m<sup>2</sup> Q3W) or nab-paclitaxel (100&#160;mg/m<sup>2</sup> weekly), finding no significant differences in OS and PFS, but significantly less neutropenia grade III (32% vs 26%) and grade IV (33% vs 14%) and neuropathy grade III (11% vs &lt;&#160;1%) and grade IV (3% vs 0%) for nab-paclitaxel. Nab-paclitaxel was associated with a significantly increased incidence of thrombocytopenia grade III (13% vs 5%) and IV (7% vs 2%) and anaemia grade III (22% vs 5%) and IV (6% vs &lt;&#160;1%) [<xref ref-type="bibr" rid="CR98">98</xref>]. Due to the lack of improved survival outcomes with nab-paclitaxel and its higher incidence of severe peripheral sensory neuropathy, paclitaxel and docetaxel are typically preferred. In this chapter, paclitaxel and nab-paclitaxel are discussed together since the active compound of nab-paclitaxel in tumour cells is still paclitaxel.</p><p id="Par31">Taxanes bind to the binding site for GTP on microtubules (&#946;-tubulin) and stabilise the peeling off and polymerisation of the protofilaments of microtubules, leading to G2-M arrest, resulting in cell apoptosis [<xref ref-type="bibr" rid="CR91">91</xref>]. Different effects are observed depending on taxane concentration, with docetaxel having a higher binding site affinity than paclitaxel. At high concentrations, taxanes induce cell apoptosis. However, at low concentrations (or high concentrations after adaptation to taxane treatment), taxanes alter mitosis and disturb the formation of micronuclei and aggregation of chromosomes, leading to DNA damage and the activation of the cGAS/STING pathway [<xref ref-type="bibr" rid="CR91">91</xref>]. The cGAS/STING pathway activates the innate immune system and stimulates macrophage activity, providing a synergetic effect with immune checkpoint inhibitors [<xref ref-type="bibr" rid="CR99">99</xref>]. Additionally, paclitaxel binds toll-like receptor 4 (TLR-4), leading to the secretion of pro-inflammatory cytokines and enhancing inflammation response by activating dendritic, NK- and cytotoxic T-cells [<xref ref-type="bibr" rid="CR100">100</xref>]. Moreover, paclitaxel and docetaxel inhibit the accumulation of endothelial progenitor cells (EPC) and induce the expression of thrombospondin-1 (TSP-1) in the tumour microenvironment, leading to the inhibition of angiogenesis [<xref ref-type="bibr" rid="CR101">101</xref>].</p></sec><sec id="Sec17"><title>Docetaxel</title><sec id="Sec18"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par32">Docetaxel is hydrophobic, and more than 90% is bound in plasma to albumin, &#945;1-acid glycoprotein (AAG), and lipoprotein (mainly high-density and low-density lipoprotein) [<xref ref-type="bibr" rid="CR102">102</xref>]. Docetaxel is primarily eliminated by CYP3A4 enzymes and excreted through biliary excretion into the faeces with less than 5% renal excretion [<xref ref-type="bibr" rid="CR92">92</xref>]. The PK of docetaxel appear to be linear over the clinically relevant range of doses, with exposure to docetaxel increasing proportionately with the dose [<xref ref-type="bibr" rid="CR92">92</xref>]. Covariates that influence docetaxel clearance are age, BSA, albumin and AAG concentrations, and hepatic function [<xref ref-type="bibr" rid="CR103">103</xref>]. Although many covariates for docetaxel PKs have been identified, most variability in exposure remains unexplained. In clinical practice, docetaxel is dosed based on BSA at 75 mg/m<sup>2</sup> Q3W [<xref ref-type="bibr" rid="CR95">95</xref>]. Nevertheless, administration of docetaxel solely on BSA results in a negligible reduction in interindividual variability of the PK of docetaxel [<xref ref-type="bibr" rid="CR104">104</xref>].</p><p id="Par33">Systemic docetaxel drug exposure significantly correlates with the risk of toxicity, specifically with neutropenia, but also with better survival outcomes [<xref ref-type="bibr" rid="CR105">105</xref>]. Moreover, the degree of neutropenia is associated with the efficacy of docetaxel [<xref ref-type="bibr" rid="CR106">106</xref>]. A large study involving 885 patients with advanced or metastatic NSCLC identified grade I&#8211;II and grade III&#8211;IV docetaxel-induced neutropenia as independent factors associated with improved time to progression (TTP) and OS compared to patients without neutropenia [<xref ref-type="bibr" rid="CR107">107</xref>].</p></sec><sec id="Sec19"><title>Promising Developments</title><p id="Par34">As docetaxel is mainly metabolised by CYP3A enzymes in the liver, genotyping and phenotyping of the metabolic activity of the liver could be an option. However, evidence for genotyping is limited. A study of 92 patients with solid tumours found no association between CYP3A polymorphisms and docetaxel PK [<xref ref-type="bibr" rid="CR108">108</xref>]. Another candidate for genotyping could be ABC-transporters. Studies found an association between carriers of <italic toggle="yes">ABCB1</italic> gene polymorphisms and increased exposure [<xref ref-type="bibr" rid="CR108">108</xref>] and risk of docetaxel-associated neutropenia [<xref ref-type="bibr" rid="CR109">109</xref>].</p><p id="Par35">Regarding metabolic phenotyping, an erythromycin breath test (ERMBT; <sup>14</sup>C-labelled erythromycin is administered and exhaled <sup>14</sup>C-labelled CO<sub>2</sub> is measured as an indicator for CYP3A activity) was found to explain 67% of interindividual variability of docetaxel exposure [<xref ref-type="bibr" rid="CR110">110</xref>]. Other studies showed no correlation between CYP3A(4) probes like midazolam and docetaxel clearance [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. A study by Yamamoto et al found the renal excretion of 6-&#946;-hydroxy cortisol (6-&#946;-OHF) to be significantly and highly correlated with docetaxel clearance (<italic toggle="yes">r</italic>&#160;=&#160;0.867; <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) [<xref ref-type="bibr" rid="CR113">113</xref>]. A subsequent prospective randomised study found the use of 6-&#946;-OHF reduced docetaxel interindividual variability by 46.2% compared to BSA-based dosing [<xref ref-type="bibr" rid="CR114">114</xref>]. Similar results were found for other non-invasive methods to determine the patient individual CYP3A4 phenotyping using 6-&#946;-OHF to cortisol ratio or other endogenous markers [<xref ref-type="bibr" rid="CR115">115</xref>]. Clearance of a microdose of docetaxel before treatment could potentially be linearly extrapolated to therapeutically relevant doses. However, docetaxel clearance showed no linear increase from 0.1 and 1&#160;mg microdoses to a therapeutic dose, presumable because of plasma protein binding to AAG and other lipoproteins, which might be saturated at therapeutic doses [<xref ref-type="bibr" rid="CR116">116</xref>, <xref ref-type="bibr" rid="CR117">117</xref>].</p><p id="Par36">Another promising development is the change from docetaxel administration Q3W to weekly dosing. A meta-analysis including 6 RCTs in 1018 advanced NSCLC patients investigating weekly versus Q3W of docetaxel showed a significant decrease in grade III&#8211;IV neutropenia, while OS (relative risk [RR]&#160;=&#160;1.01; 95% CI 0.76&#8211;1.42, <italic toggle="yes">p</italic>&#160;=&#160;0.785) and objective response rate (RR&#160;=&#160;0.81; 95% CI 0.47&#8211;1.40, <italic toggle="yes">p</italic>&#160;=&#160;0.465) remained unaffected [<xref ref-type="bibr" rid="CR118">118</xref>].</p><p id="Par37">Evidence on the effectiveness of TDM-guided dosing for docetaxel in NSCLC patients is still limited. A small study (<italic toggle="yes">n</italic>&#160;=&#160;30) across multiple tumour types showed that TDM-guided dosing, compared to standard BSA-based dosing, reduced interindividual variability in docetaxel exposure by 39% and variability of neutropenia by 50% when targeting at a docetaxel exposure (AUC) of 4.9 mg/L*h [<xref ref-type="bibr" rid="CR119">119</xref>]. Lastly, TDM-guided dosing could potentially be utilised for subsequent cycles in specific patient populations, such as metastatic castration-resistant prostate cancer (mCRPC) patients. A large meta-analysis of 26 RCTs (<italic toggle="yes">n</italic>&#160;=&#160;1150) identified a 1.8-fold lower docetaxel exposure and 2.2-fold lower odds of developing grade III&#8211;IV neutropenia for mCRPC patients compared to patients with other solid tumours [<xref ref-type="bibr" rid="CR120">120</xref>].</p><p id="Par38">Research data suggest a link between patient survival and neutrophil count in the first cycle, showing a potential benefit for dose reduction after the first cycle of docetaxel [<xref ref-type="bibr" rid="CR106">106</xref>]. In clinical practice, neutrophil counts are measured as part of the standard of care one day before the next cycle. Yet, the most accurate estimate of the neutrophil nadir would be obtained by measuring it approximately 8&#8211;10 days after docetaxel administration. Interestingly, a simulation study showed that one extra neutrophil measurement is sufficient to limit severe neutropenia while increasing dose intensity [<xref ref-type="bibr" rid="CR121">121</xref>]. However, to our knowledge, this has not yet been prospectively tested in clinical practice. Although promising, at present we are still hesitant to recommend docetaxel dosing based on neutrophil counts. The available evidence is based on older studies conducted when docetaxel was given as an earlier line of treatment. Currently, however, docetaxel is generally used as a third- or fourth-line therapy, where any added toxicity could be especially risky and potentially life-threatening. Moreover, an extra neutrophil measurement during treatment comes with additional logistic consequences.</p></sec><sec id="Sec20"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par39">We recommend weekly dosing of docetaxel, as it decreases the incidence of severe neutropenia while similar efficacy is maintained. However, this will impact hospital infusion care and patient visits. With regard to other promising developments, including neutrophil-guided dosing, metabolic genotyping and phenotyping, and TDM-guided dosing, more clinical evidence is needed before further recommendations can be made.</p></sec></sec><sec id="Sec21"><title>Paclitaxel and Nab-Paclitaxel</title><sec id="Sec22"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par40">Paclitaxel clearance is non-linear, which is especially apparent in up to 3-hour infusions. Its non-linear clearance is attributed to the saturation of paclitaxel transport, binding (albumin and AAG), CYP2C8-mediated metabolism, and by the formulation of paclitaxel using the solvent cremophor EL mixed 1:1 with ethanol [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. Different PK parameters have been tested for association with clinical outcome parameters of paclitaxel treatment: AUC, <italic toggle="yes">C</italic><sub>max,</sub> and time above threshold concentration (<italic toggle="yes">T</italic><sub>&gt;concentration</sub>). Time above paclitaxel plasma concentration of 0.05&#160;&#956;mol/L (<italic toggle="yes">T</italic><sub>&gt;0.05</sub>) appeared to be the best predictor of paclitaxel-associated neutropenia, paclitaxel-induced polyneuropathy (cumulative chemotherapy-induced peripheral neuropathy [CIPN]), and clinical outcomes [<xref ref-type="bibr" rid="CR123">123</xref>]. Some studies even suggest a higher time above the threshold (<italic toggle="yes">T</italic><sub>&gt;0.10</sub>) [<xref ref-type="bibr" rid="CR124">124</xref>]. Like docetaxel, paclitaxel is primarily cleared by the liver and eliminated through biliary excretion. Hence, patients with impaired liver function or liver metastases have a decreased paclitaxel clearance, leading to increased exposure and an increased risk of paclitaxel-induced toxicity [<xref ref-type="bibr" rid="CR125">125</xref>].</p><p id="Par41">Nab-paclitaxel is albumin-bound paclitaxel. The albumin part binds to albondin (gp60) receptors on endothelial cells and paclitaxel-albumin complexes are carried across the endothelial membrane (transcytosis) into surrounding tissues, including tumour tissue. Accumulation of albumin-paclitaxel complexes is increased by a high amount of leaky tumour vasculature and by the albumin binding activity of secreted protein acidic and rich in cysteine (SPARC) in tumour tissue [<xref ref-type="bibr" rid="CR96">96</xref>]. The albumin-paclitaxel formulation rarely shows infusion or hypersensitivity reactions. Therefore, nab-paclitaxel does not require prophylactic medication and can be administered by intravenous infusion 30 minutes faster compared to 1- or 3-h paclitaxel and 1-h docetaxel infusions [<xref ref-type="bibr" rid="CR126">126</xref>]. Nab-paclitaxel PK show linear elimination with a higher free fraction of paclitaxel (6.2%) [<xref ref-type="bibr" rid="CR127">127</xref>] compared to paclitaxel cremophor EL (2.3%) [<xref ref-type="bibr" rid="CR128">128</xref>]. Still, since albumin has multiple times higher molecular weight compared to paclitaxel, nab-paclitaxel is administered at a higher dose of 300&#160;mg/m<sup>2</sup> versus 175&#160;mg/m<sup>2</sup> for paclitaxel cremophor EL Q3W [<xref ref-type="bibr" rid="CR96">96</xref>]. At high dosages of nab-paclitaxel, elimination is non-linear, indicating a possible saturation of metabolism at high paclitaxel concentrations [<xref ref-type="bibr" rid="CR122">122</xref>]. Clearance of nab-paclitaxel is equal to clearance of its active component paclitaxel. Hence, clearance is mainly by the liver, and dose reduction is recommended for patients with impaired liver function [<xref ref-type="bibr" rid="CR126">126</xref>].</p><p id="Par42">Exposure to nab-paclitaxel is associated with toxicity, including (febrile) neutropenia and alopecia, but without acute or infusion-related hypersensitivity systemic reactions [<xref ref-type="bibr" rid="CR129">129</xref>]. Moreover, nab-paclitaxel is still associated with cumulative CIPN, even though the formulation of nab-paclitaxel was developed to reduce peripheral neuropathy compared to paclitaxel and docetaxel. However, studies have been conflicting. The latest meta-analysis, including 24 studies, found a significantly higher incidence of peripheral neuropathy for nab-paclitaxel versus paclitaxel (16% vs 5%) [<xref ref-type="bibr" rid="CR130">130</xref>].</p></sec><sec id="Sec23"><title>Promising Developments</title><p id="Par43">Paclitaxel's time above plasma concentration of 0.05 &#956;mol/L (<italic toggle="yes">T</italic><sub>&gt;0.05</sub>) is associated with both efficacy and toxicity outcomes, suggesting the potential for TDM-guided dosing. Several prospective RCTs in patients with advanced NSCLC have been conducted, aiming for a target time above 0.05 &#956;mol/L paclitaxel plasma concentration between 26 and 31 hours or &#8805;&#160;15&#160;h without a clearly defined upper limit for 0.10&#160;&#956;mol/L (<italic toggle="yes">T</italic><sub>&gt;0.10</sub>) [<xref ref-type="bibr" rid="CR123">123</xref>]. All studies demonstrated reduced paclitaxel-associated toxicity, primarily neuropathy, while efficacy was not significantly different compared to BSA-based dosing. For nab-paclitaxel, literature concerning TDM-guided dosing in NSCLC patients based on a specific plasma concentration is limited. A study by Chen et al in 150 patients with various tumours receiving either 100&#160;mg/m<sup>2</sup> weekly or 300&#160;mg/m<sup>2</sup> Q3W nab-paclitaxel found time above the <italic toggle="yes">C</italic><sub>threshold</sub> of 720&#160;&#956;g/L (0.86 and 3.75&#160;h, respectively) to be associated with a &#8805;&#160;50% decrease in neutrophils and that the development of neutropenia to be positively associated with age (but not with hepatic function, tumour type, gender or dosing schedule) [<xref ref-type="bibr" rid="CR127">127</xref>].</p><p id="Par44">Genotyping and metabolic phenotyping for paclitaxel, and thus nab-paclitaxel, may also be an opportunity, although to a lesser extent. Ovarian cancer patients (<italic toggle="yes">n</italic>&#160;=&#160;93) carrying the <italic toggle="yes">CYP2C8*3</italic> allele showed a significantly increased paclitaxel AUC and 11% lower clearance than non-carriers [<xref ref-type="bibr" rid="CR131">131</xref>]. Unsurprisingly, patients carrying the <italic toggle="yes">CYP2C8*3</italic> allele were associated with an increased risk of paclitaxel-associated neurotoxicity and higher incidences of complete response compared to non-carriers (55% vs 23%) [<xref ref-type="bibr" rid="CR132">132</xref>]. Lastly, having an <italic toggle="yes">ABCB1</italic> dysfunctional allele was associated with an increase in paclitaxel-associated neuropathy [<xref ref-type="bibr" rid="CR133">133</xref>], gastro-intestinal toxicity, and possibly increased survival outcomes relative to non-carriers [<xref ref-type="bibr" rid="CR134">134</xref>].</p><p id="Par45">Weekly dosing of paclitaxel instead of Q3W has shown favourable results. A meta-analysis including 10 RCTs in 3504 advanced solid tumour patients showed that weekly paclitaxel treatment reduces severe neutropenia and sensor neuropathy (10 RCTs; odds ratio [OR]&#160;=&#160;0.49; 95% CI 0.30&#8211;0.82) and improves response rates (5 NSCLC RCTs; OR&#160;=&#160;1.24; 95% CI 1.01&#8211;1.53) compared to Q3W [<xref ref-type="bibr" rid="CR135">135</xref>]. For nab-paclitaxel, multiple studies show that reducing the dosing interval of nab-paclitaxel to 100&#160;mg/m<sup>2</sup> weekly resulted in improved efficacy and less toxicity compared to 300&#160;mg/m<sup>2</sup> Q3W [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>].</p><p id="Par46">In pancreas cancer studies, the grade of nab&#8211;paclitaxel-induced neutropenia of weekly dosing seems to be an independent predictive for grade III&#8211;IV versus grade I&#8211;II neutropenia (19.2 vs 11.3 months, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.001) and prognostic factor (HR&#160;=&#160;0.79; 95% CI 0.69&#8211;0.91, <italic toggle="yes">p</italic>&#160;=&#160;0.001) associated with increased OS [<xref ref-type="bibr" rid="CR138">138</xref>]. In a prospective study by Scheithauer et al, 421 patients with metastatic pancreas cancer receiving nab-paclitaxel 125 mg/m<sup>2</sup> weekly. 172 (41%) patients received a dose reduction and 300 (71%) received a dose delay. Patients who had a dose reduction and dose delay completed more cycles and received higher cumulative dosing compared to patients not receiving a dose reduction. Furthermore, patients receiving no dose reduction and dose delay were significantly associated with decreased OS compared to patients receiving dose reduction (6.9 vs 11.4 months, HR&#160;=&#160;1.93; 95% CI 1.53&#8211;2.44, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) and dose delay (6.2 vs 10.1 months, HR&#160;=&#160;2.05; 95% CI 1.60&#8211;2.63, <italic toggle="yes">p</italic>&#160;&lt;&#160;0.0001) [<xref ref-type="bibr" rid="CR139">139</xref>].</p></sec><sec id="Sec24"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par47">For paclitaxel, we recommend starting the first cycle using BSA-based dosing for Q3W dosing of paclitaxel, followed by blood sampling around 24&#160;h after the start of infusion and a TDM-guided dose aiming at the time above plasma concentration of 0.05&#160;&#956;mol/L (<italic toggle="yes">T</italic><sub>&gt;0.05</sub>) of 26&#8211;31&#160;h based on the recommendation by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) [<xref ref-type="bibr" rid="CR123">123</xref>]. A validated commercial assay is readily available including a decision support tool for routine paclitaxel TDM [<xref ref-type="bibr" rid="CR140">140</xref>]. If neutropenia grade III&#8211;IV occurred in the previous cycle, the dose of paclitaxel is reduced. Moreover, weekly dosing of paclitaxel may ameliorate the toxicity profile of paclitaxel without compromising efficacy (see Table <xref rid="Tab1" ref-type="table">1</xref>). We recommend weekly dosing of nab-paclitaxel, as it offers similar opportunities to reduce toxicity while enhancing efficacy, as with paclitaxel.</p></sec></sec><sec id="Sec25"><title>Gemcitabine</title><sec id="Sec26"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par48">Gemcitabine (dFdC) is an analogue of cytidine with the addition of two fluorine substituents on the 2&#8217; position of the furanose ring [<xref ref-type="bibr" rid="CR141">141</xref>]. As dFdC is a hydrophilic prodrug, it must first be transported into the cell by membrane nucleoside transporters (mainly human equilibrative nucleoside transporters [hENTs]). Once inside the cell, dFdC is activated through intracellular phosphorylation to gemcitabine monophosphate (dFdCMP) primarily by the rate-limiting enzyme deoxycytidine kinase (dCK) [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>]. Additional phosphorylation creates the active metabolites gemcitabine di-(dFdCDP) and triphosphate (dFdCTP) and prevents them from being excreted from the cell [<xref ref-type="bibr" rid="CR143">143</xref>].</p><p id="Par49">Gemcitabine clearance from plasma is linear and independent of dosing up to 3650 mg/m<sup>2</sup> [<xref ref-type="bibr" rid="CR144">144</xref>]. However, the phosphorylation of gemcitabine intracellular to dFdCDP and dfdCTP is saturated at high concentrations of gemcitabine [<xref ref-type="bibr" rid="CR145">145</xref>]. Gemcitabine is inactivated mainly by deoxycytidine deaminase (dCDA) to di-fluoro-deoxyuridine (dFdU) or phosphorylated gemcitabine by deoxycytidylate deaminase to phosphorylated uridine (e.g., dFdCMP to dFdUMP) and subsequently to dFdU [<xref ref-type="bibr" rid="CR141">141</xref>]. Gemcitabine and dFdU are excreted from the cell since they are not a substrate for pyrimidine nucleoside phosphorylases [<xref ref-type="bibr" rid="CR144">144</xref>]. The dCDA is expressed at high levels in the plasma and the liver [<xref ref-type="bibr" rid="CR142">142</xref>]. Hence, clearance of gemcitabine is fast (<italic toggle="yes">t</italic><sub>1/2</sub>&#160;=&#160;2&#8211;15&#160;min), with 50&#8211;95% of gemcitabine metabolised into dFdU and excreted via the urine within 24&#160;h (&gt;&#160;90% within one week as either gemcitabine [1%] or dFdU [99%]) [<xref ref-type="bibr" rid="CR143">143</xref>]. Since dCK is the rate-limiting enzyme for activation of gemcitabine, saturation or deficiency of dCK decreases the effectiveness of gemcitabine [<xref ref-type="bibr" rid="CR142">142</xref>]. Moreover, phosphorylated dFdU still present in the (tumour) cell can again be incorporated in DNA (and RNA) and is associated with cytotoxicity, increasing with prolonged exposure [<xref ref-type="bibr" rid="CR146">146</xref>]. Covariates that influence gemcitabine clearance, and thus exposure, are creatinine clearance, sex, <italic toggle="yes">dCDA</italic> polymorphisms, and BSA [<xref ref-type="bibr" rid="CR147">147</xref>], while age seems to have no influence [<xref ref-type="bibr" rid="CR148">148</xref>]. Currently, gemcitabine is administered based on BSA 1000&#8211;1250&#160;mg/m<sup>2</sup> weekly and administrated in 30&#160;min (40&#160;mg/m<sup>2</sup>/min), resulting in dFdC plasma concentration of 20&#8211;60&#160;&#956;M, whereas saturation of dCK is already reached at 15&#8211;20&#160;&#956;M [<xref ref-type="bibr" rid="CR145">145</xref>].</p><p id="Par50">The phosphorylated gemcitabine anabolites have multiple intracellular targets influencing DNA synthesis. Gemcitabine monophosphate inhibits ribonucleotide reductase (RNR) needed for producing deoxynucleotides, further stimulating the incorporation of gemcitabine anabolites into DNA [<xref ref-type="bibr" rid="CR149">149</xref>]. dFdCTP inhibits DNA polymerase and is incorporated into DNA, leading to direct termination of chain elongation, preventing DNA repair enzymes from detecting DNA chain termination and inducing apoptosis [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>].</p></sec><sec id="Sec27"><title>Promising Developments</title><p id="Par51">To avoid dCK saturation and to increase intracellular accumulation of dFdCTP, prolonged gemcitabine infusion times at 10 mg/m<sup>2</sup>/min have been proposed. Indeed, administration at 10 mg/m<sup>2</sup>/min increased the accumulation of dFdCTP. However, at the same time, gemcitabine-induced toxicity was increased compared to conventional 30-minute infusion without affecting survival outcomes [<xref ref-type="bibr" rid="CR150">150</xref>]. Literature on this topic is conflicting. A study by Lee et al (<italic toggle="yes">n</italic>&#160;=&#160;48) examining the toxicity and efficacy of prolonged gemcitabine infusion (1000&#160;mg/m<sup>2</sup>) combined with cisplatin (25&#160;mg/m<sup>2</sup>) in elderly or poor performance status patients with NSCLC found comparable response rates and toxicity levels to those in patients with good performance status [<xref ref-type="bibr" rid="CR151">151</xref>]. Similarly, an observational study (<italic toggle="yes">n</italic>&#160;=&#160;39) by Locher et al reported similar outcomes for elderly patients (&#8805;&#160;70&#160;years) with pancreatic cancer [<xref ref-type="bibr" rid="CR152">152</xref>]. As survival outcomes remain unaffected, but toxicity increases, this suggests that the intracellular concentrations of gemcitabine achieved with the current dosage are within the therapeutic range. Therefore, administering a reduced dose of gemcitabine over an extended period could maintain similar efficacy (being within the therapeutic exposure range) while reducing toxicity. Hence, another proposed treatment regimen for gemcitabine is the prolonged infusion of weekly low-dose gemcitabine (PLDG) for 250&#160;mg/m<sup>2</sup> over 6&#160;h (=&#160;0.7&#160;mg/m<sup>2</sup>/min). Compared to the standard administration of gemcitabine, an extensive study by Patil et al in 308 advanced SCLC patients showed no significant difference in median OS, PFS, and adverse event rate for PLDG compared to standard weekly gemcitabine dosing of 1000&#160;mg/m<sup>2</sup> in 30&#160;min [<xref ref-type="bibr" rid="CR153">153</xref>].</p><p id="Par52">Likewise, for gemcitabine, dosing based on neutropenia as a prognostic factor for treatment outcome is possible [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. A large study by Pallis et al looked at docetaxel-gemcitabine treatment in advanced NSCLC patients (<italic toggle="yes">n</italic>&#160;=&#160;885) and found a significantly increased median OS of 12.5 (95% CI 11.3&#8211;13.7) and 11.2 months (95% CI 9.2&#8211;13.2) for mild (grade I&#8211;II) and severe (grade III&#8211;IV) neutropenia compared to 7.9 months (95% CI 6.9&#8211;8.8) for absence (grade 0) of neutropenia [<xref ref-type="bibr" rid="CR107">107</xref>]. However, to our knowledge, only one large RCT (Phase III) has been conducted, describing 402 metastatic pancreas cancer patients receiving gemcitabine monotherapy and showed a significant association between decreased OS and gemcitabine-induced toxicity [<xref ref-type="bibr" rid="CR139">139</xref>].</p><p id="Par53">Genotyping for <italic toggle="yes">dCK</italic> [<xref ref-type="bibr" rid="CR154">154</xref>] and tumour expression analysis of <italic toggle="yes">hENT</italic> [<xref ref-type="bibr" rid="CR155">155</xref>] show promising results as a predictor of gemcitabine treatment outcomes. A meta-analysis including 29 studies of 253 patients with advanced pancreatic carcinoma found an association between higher <italic toggle="yes">hENT1</italic> tumour expression and increased OS (HR&#160;=&#160;0.674; 95% CI 0.509&#8211;0.893, <italic toggle="yes">p</italic>&#160;=&#160;0.006), without an increase in PFS (HR&#160;=&#160;0.740; 95% CI 0.517&#8211;1.059, <italic toggle="yes">p</italic>&#160;=&#160;0.100) [<xref ref-type="bibr" rid="CR156">156</xref>]. To further reduce interpatient variability, TDM-guided dosing for gemcitabine could be possible with a target concentration of 20&#160;&#956;M (~&#160;5&#160;&#956;g/mL) corresponding with saturation levels of dCK [<xref ref-type="bibr" rid="CR157">157</xref>] or <italic toggle="yes">C</italic><sub>max</sub> correlated with gemcitabine-induced toxicity [<xref ref-type="bibr" rid="CR158">158</xref>]. However, gemcitabine&#8217;s standard of care is administrated in 30&#160;min, making the blood sampling needed hours after administration difficult. Moreover, immunoassays for gemcitabine are still being developed and optimised [<xref ref-type="bibr" rid="CR157">157</xref>].</p></sec><sec id="Sec28"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par54">At present, we cannot recommend prolonging the gemcitabine infusion time, as more research is needed to determine whether a prolonged infusion of low-dose gemcitabine can maintain efficacy while reducing toxicity. Moreover, whether extended hospital stays due to longer infusion times outweigh the costs has yet to be investigated.</p></sec></sec><sec id="Sec29"><title>Vinorelbine</title><sec id="Sec30"><title>Pharmacokinetics, Pharmacodynamics and Current Practice in Dosing</title><p id="Par55">Vinorelbine is a semisynthetic vinca alkaloid that reversibly binds to the positive end of a microtubule, destabilising its function. The primary binding site of vinorelbine is &#946;-tubulin, which induces a conformational change that increases the affinity of tubulin for itself and influences the dynamics of lengthening and shortening and increases of the microtubule. At high concentrations, vinorelbine stimulates microtubule depolymerisation and mitotic spindle destruction, and at low concentrations, it blocks mitotic progression [<xref ref-type="bibr" rid="CR159">159</xref>]. Vinorelbine is highly lipophilic and primarily metabolised in the liver (&lt;&#160;20% through urinary excretion) and excreted unchanged in bile to vinorelbine N-oxide and deacetyl-vinorelbine [<xref ref-type="bibr" rid="CR160">160</xref>]. Vinorelbine clearance is shown to be correlated with creatinine clearance but not with age and BSA [<xref ref-type="bibr" rid="CR161">161</xref>]. However, administration of vinorelbine is currently still based on BSA. Due to a relatively low oral bioavailability of 40%, a higher dose is given per os compared to intravenous administration (60&#160;mg/m<sup>2</sup> vs 25&#8211;30&#160;mg/m<sup>2</sup>, respectively) [<xref ref-type="bibr" rid="CR162">162</xref>].</p><p id="Par56">The hepatic clearance of vinorelbine is shown to be associated with <italic toggle="yes">ABCB1</italic> [<xref ref-type="bibr" rid="CR161">161</xref>] and partly with <italic toggle="yes">CYP3A</italic> genotypes [<xref ref-type="bibr" rid="CR163">163</xref>]. Nevertheless, clearance of vinorelbine in plasma is high and approaches hepatic blood flow, indicating that the overall capacity of the liver in removing vinorelbine is high (i.e., maximised to hepatic blood flow) [<xref ref-type="bibr" rid="CR160">160</xref>]. Only small prospective studies have investigated the relationship between vinorelbine clearance and hepatic function and have found no effect of liver impairment on the PK of vinorelbine [<xref ref-type="bibr" rid="CR161">161</xref>, <xref ref-type="bibr" rid="CR164">164</xref>]. The primary vinorelbine-induced toxicity is neutropenia, anaemia, and thrombocytopenia, with the maximum dose of vinorelbine intravenously set at 35 mg/m<sup>2</sup> due to the dose-limiting toxicity of neutropenia [<xref ref-type="bibr" rid="CR162">162</xref>].</p></sec><sec id="Sec31"><title>Promising Developments</title><p id="Par57">Body surface area is associated with the degree of myelosuppression (i.e., neutropenia) in vinorelbine treatment [<xref ref-type="bibr" rid="CR161">161</xref>]. A study in metastatic breast cancer patients (<italic toggle="yes">n</italic>&#160;=&#160;25) showed fixed-dose vinorelbine (+ capecitabine) to be more effective and safer compared to dosing based on BSA and found no association between vinorelbine clearance and BSA [<xref ref-type="bibr" rid="CR165">165</xref>]. Gusella et al (<italic toggle="yes">n</italic>&#160;=&#160;82) found high blood concentrations of vinorelbine and its metabolites associated with increased toxicity but not efficacy in NSCLC patients [<xref ref-type="bibr" rid="CR166">166</xref>]. Another study (<italic toggle="yes">n</italic>&#160;=&#160;201) found high BMI to be associated with increased vinorelbine-induced toxicity but found no association for the covariates sex, chemotherapeutic regimen (monotherapy vs combination therapy), prior chemotherapy, and dose of vinorelbine (&lt;&#160;40 vs &#8805;&#160;40&#160;mg) [<xref ref-type="bibr" rid="CR167">167</xref>]. In contrast, Nobili et al (<italic toggle="yes">n</italic>&#160;=&#160;83) found an association between vinorelbine toxicity and covariates age and sex [<xref ref-type="bibr" rid="CR168">168</xref>].</p><p id="Par58">The clearance of technetium labelled sestamibi (<sup>99m</sup>Tc-MIBI) and midazolam could be used for phenotyping of ABCB1 and CYP3A, and clearance of both substances significantly correlated to vinorelbine clearance. However, as vinorelbine clearance is associated with creatinine clearance, the partial correlation between vinorelbine clearance and hepatic <sup>99m</sup>TC-MIBI clearance was 0.44 after adjusting for creatinine clearance [<xref ref-type="bibr" rid="CR161">161</xref>].</p><p id="Par59">Metronomic dosing of vinorelbine has also been investigated with promising results. A meta-analysis including 509 stage IIIb/IV NSCLC (11 RCTs) identified a similar efficacy compared to monotherapy vinorelbine, with a median PFS of 3.5 months (95% CI 2.5&#8211;4.4) and OS of 8.2 months (95% CI 7.2&#8211;9.2), and fewer and lighter adverse events with only a 16% incidence of grade III&#8211;IV adverse events (95% CI 10&#8211;22) with 9% neutropenia (95% CI 2&#8211;20) [<xref ref-type="bibr" rid="CR169">169</xref>]. Furthermore, adding granulocyte colony-stimulating factor (G-CSF) could increase the dose intensity of vinorelbine for both daily and weekly dosing without a corresponding increase in toxicity [<xref ref-type="bibr" rid="CR170">170</xref>].</p><p id="Par60">The limited and conflicting data, particularly in NSCLC patients, prevent a definitive conclusion regarding the relationship between PK parameters and PD efficacy and toxicity endpoints of vinorelbine treatment. In addition, while prolonged infusion of vinorelbine over 96&#160;h in a dose of 8&#160;mg/m<sup>2</sup> has demonstrated considerable therapeutic activity, it is associated with severe toxicities, affecting half of the patients treated [<xref ref-type="bibr" rid="CR171">171</xref>]. These results do not indicate an advantage of prolonged infusion compared to conventional weekly administration.</p></sec><sec id="Sec32"><title>Recommendations and Opportunities for Treatment Optimisation</title><p id="Par61">Currently, we still recommend dosing at BSA. There is insufficient evidence to suggest dosing differently, especially since BSA seems to correlate with toxicity. However, a clear PK/PD relationship between plasma exposure and response to vinorelbine has yet to be found (see Table <xref rid="Tab1" ref-type="table">1</xref>), and TDM-guided dosing is not advised.</p></sec></sec><sec id="Sec33"><title>Concluding Remarks</title><p id="Par62">Currently, all classical cytotoxic drugs, except for carboplatin, in NSCLC are dosed based on BSA. In this review, we showed many opportunities for precision dosing of classical anticancer drugs to improve NSCLC treatment outcomes in which the incidence of severe toxicity can be reduced, and efficacy can be improved (see Table <xref rid="Tab1" ref-type="table">1</xref>). An important point to note is that while the type of cancer may not necessarily alter PK, it could impact efficacy (PD), making extrapolation to NSCLC patients potentially unfeasible. To address this concern, we have added footnotes to highlight the recommendations that were not investigated in NSCLC populations.</p><p id="Par63">While multiple promising developments exist for cisplatin, pemetrexed, and vinorelbine, these opportunities are not yet for direct implementation and require further research. In the case of carboplatin, we recommend immediately adopting cystatin C to individualise the dose of carboplatin. We suggest weekly dosing for docetaxel, paclitaxel, and nab-paclitaxel to minimise toxicity while maintaining treatment efficacy. Specifically, for paclitaxel, when administered in a 21-day cycle, we recommend the use of TDM-guided dosing following the international IATDMCT guidelines. Finally, we advise investigating prolonging infusion times for gemcitabine to reduce toxicity without compromising effectiveness.</p><p id="Par64">Although dose individualisation strategies have been shown to significantly improve health outcomes and reduce side effects, implementing precision dosing opportunities may also pose challenges. For example, individualised dosing based on TDM requires extra time and sampling, clear PK/PD relationships (often tumour-specific), logistical planning, dosing decision support, and facilities [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>]. Therefore, further research is needed to ensure that these strategies are both cost effective and feasible for routine clinical settings without overstraining existing healthcare systems.</p><p id="Par65">Currently, much of the effort toward dose optimisation remains within the academic sphere. A major barrier to the implementation of precision dosing recommendations, based on readily available evidence, is that academic research is often not integrated or adopted by regulatory agencies or license holders. The findings of this review, alongside other academic dose optimisation studies, should reach governments, regulatory agencies, license holders, and key healthcare professionals. These recommendations should not be confined to stay as an academic exercise but should be actively considered by all stakeholders. However, there is limited commercial incentive for license holders to adjust their labelling. This is why initiatives by regulatory agents like the FDA&#8217;s Project Renewal, which aims to update prescribing information (i.e., labelling) for older oncology drugs, are so critical [<xref ref-type="bibr" rid="CR174">174</xref>]. Such initiatives help to ensure that information remains clinically meaningful and scientifically up-to-date.</p><p id="Par66">In conclusion, this narrative review provided a comprehensive overview of studies focused on individualised dosing opportunities of classical cytotoxic drugs in patients with NSCLC and outlined the most promising, readily implementable dose optimisation strategies. Some of these approaches have already been proven in multiple prospective studies and can be directly implemented into clinical practice, requiring minimal further research. Finally, although there is still much to be done to optimise classical cytotoxic therapy dosing strategies to individual patients&#8217; characteristics in the era of precision medicine, promising developments and opportunities are numerous and encouraging.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors declare that there are no acknowledgements, including no funding or grants.</p></ack><notes><title>Declarations</title><notes notes-type="COI-statement"><title>Conflict of interest</title><p>The authors declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.</p></notes><notes id="FPar1" notes-type="funding"><title>Funding</title><p id="Par67">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></notes><notes id="FPar2"><title>Ethics approval</title><p id="Par68">Not applicable.</p></notes><notes id="FPar3"><title>Consent to participate</title><p id="Par69">Not applicable.</p></notes><notes id="FPar4"><title>Consent for publication</title><p id="Par70">Not applicable.</p></notes><notes id="FPar5"><title>Availability of data and material</title><p id="Par71">Not applicable.</p></notes><notes id="FPar8"><title>Code availability</title><p id="Par711">Not applicable.</p></notes><notes id="FPar6" notes-type="author-contribution"><title>Author contributions</title><p id="Par74">M.P. Kicken contributed to conceptualisation, formal analysis, investigation, methodology, project administration, supervision, validation, visualization, writing&#8212;original draft and writing&#8212;review &amp; editing. R. ter Heine, and M.J. Deenen contributed to conceptualization, formal analysis, investigation, methodology, supervision, validation, writing&#8212;original draft and writing&#8212;review &amp; editing. B.E.E.M. van den Borne, A.J. van der Wekken, and M.M. van den Heuvel contributed to investigation, writing&#8212;review &amp; editing.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>3</issue><fpage>229</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3322/caac.21834</pub-id><pub-id pub-id-type="pmid">38572751</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229&#8211;63.<pub-id pub-id-type="pmid">38572751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travis</surname><given-names>WD</given-names></name></person-group><article-title>Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas</article-title><source>Mod Pathol</source><year>2012</year><volume>25</volume><issue>Suppl 1</issue><fpage>S18</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2011.150</pub-id><pub-id pub-id-type="pmid">22214967</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;25(Suppl 1):S18-30.<pub-id pub-id-type="pmid">22214967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/modpathol.2011.150</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remon</surname><given-names>J</given-names></name><name name-style="western"><surname>Soria</surname><given-names>JC</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S</given-names></name></person-group><article-title>Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><issue>12</issue><fpage>1637</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.08.1994</pub-id><pub-id pub-id-type="pmid">34481037</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637&#8211;42.<pub-id pub-id-type="pmid">34481037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.08.1994</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendriks</surname><given-names>LE</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>KM</given-names></name><name name-style="western"><surname>Menis</surname><given-names>J</given-names></name><name name-style="western"><surname>Mok</surname><given-names>TS</given-names></name><name name-style="western"><surname>Nestle</surname><given-names>U</given-names></name><name name-style="western"><surname>Passaro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2023</year><volume>34</volume><issue>4</issue><fpage>358</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.12.013</pub-id><pub-id pub-id-type="pmid">36669645</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358&#8211;76.<pub-id pub-id-type="pmid">36669645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2022.12.013</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeRidder</surname><given-names>L</given-names></name><name name-style="western"><surname>Rubinson</surname><given-names>DA</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name><name name-style="western"><surname>Traverso</surname><given-names>G</given-names></name></person-group><article-title>The past, present, and future of chemotherapy with a focus on individualization of drug dosing</article-title><source>J Control Release</source><year>2022</year><volume>352</volume><fpage>840</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.10.043</pub-id><pub-id pub-id-type="pmid">36334860</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">DeRidder L, Rubinson DA, Langer R, Traverso G. The past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Control Release. 2022;352:840&#8211;60.<pub-id pub-id-type="pmid">36334860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.10.043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Holford</surname><given-names>NH</given-names></name></person-group><article-title>Mechanism-based concepts of size and maturity in pharmacokinetics</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2008</year><volume>48</volume><fpage>303</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.48.113006.094708</pub-id><pub-id pub-id-type="pmid">17914927</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303&#8211;32.<pub-id pub-id-type="pmid">17914927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pharmtox.48.113006.094708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felici</surname><given-names>A</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>Dosing strategies for anticancer drugs: the good, the bad and body-surface area</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><issue>13</issue><fpage>1677</fpage><lpage>1684</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(02)00151-X</pub-id><pub-id pub-id-type="pmid">12175683</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38(13):1677&#8211;84.<pub-id pub-id-type="pmid">12175683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0959-8049(02)00151-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>D</given-names></name><name name-style="western"><surname>Rao</surname><given-names>GG</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>SC</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>KLR</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Crona</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Precision dosing: public health need, proposed framework, and anticipated impact</article-title><source>Clin Transl Sci</source><year>2017</year><volume>10</volume><issue>6</issue><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/cts.12490</pub-id><pub-id pub-id-type="pmid">28875519</pub-id><pub-id pub-id-type="pmcid">PMC5698804</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, et al. Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci. 2017;10(6):443&#8211;54.<pub-id pub-id-type="pmid">28875519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.12490</pub-id><pub-id pub-id-type="pmcid">PMC5698804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>R</given-names></name><name name-style="western"><surname>Halford</surname><given-names>S</given-names></name><name name-style="western"><surname>Symeonides</surname><given-names>SN</given-names></name></person-group><article-title>Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective</article-title><source>Front Oncol</source><year>2023</year><volume>13</volume><fpage>1144056</fpage><pub-id pub-id-type="doi">10.3389/fonc.2023.1144056</pub-id><pub-id pub-id-type="pmid">36937434</pub-id><pub-id pub-id-type="pmcid">PMC10020863</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Murphy R, Halford S, Symeonides SN. Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective. Front Oncol. 2023;13:1144056.<pub-id pub-id-type="pmid">36937434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2023.1144056</pub-id><pub-id pub-id-type="pmcid">PMC10020863</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodney</surname><given-names>S</given-names></name><name name-style="western"><surname>Banerji</surname><given-names>U</given-names></name></person-group><article-title>Optimizing the FDA's Project Optimus: opportunities and challenges</article-title><source>Nat Rev Clin Oncol</source><year>2024</year><volume>21</volume><issue>3</issue><fpage>165</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00853-z</pub-id><pub-id pub-id-type="pmid">38129533</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Rodney S, Banerji U. Optimizing the FDA&#8217;s Project Optimus: opportunities and challenges. Nat Rev Clin Oncol. 2024;21(3):165&#8211;6.<pub-id pub-id-type="pmid">38129533</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-023-00853-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Vijgh</surname><given-names>WJ</given-names></name></person-group><article-title>Clinical pharmacokinetics of carboplatin</article-title><source>Clin Pharmacokinet</source><year>1991</year><volume>21</volume><issue>4</issue><fpage>242</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.2165/00003088-199121040-00002</pub-id><pub-id pub-id-type="pmid">1760899</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet. 1991;21(4):242&#8211;61.<pub-id pub-id-type="pmid">1760899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199121040-00002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">FDA. Food and Drug Administration - Cisplatin injection - Product information. 2021. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018057s092lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018057s092lbl.pdf</ext-link>. Accessed 05 Dec 2024.</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griesinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Korol</surname><given-names>EE</given-names></name><name name-style="western"><surname>Kayaniyil</surname><given-names>S</given-names></name><name name-style="western"><surname>Varol</surname><given-names>N</given-names></name><name name-style="western"><surname>Ebner</surname><given-names>T</given-names></name><name name-style="western"><surname>Goring</surname><given-names>SM</given-names></name></person-group><article-title>Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis</article-title><source>Lung Cancer</source><year>2019</year><volume>135</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.07.010</pub-id><pub-id pub-id-type="pmid">31446995</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2019;135:196&#8211;204.<pub-id pub-id-type="pmid">31446995</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2019.07.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Huang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HH</given-names></name><name name-style="western"><surname>Wang</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>YF</given-names></name></person-group><article-title>Association of sodium thiosulfate with risk of ototoxic effects from platinum-based chemotherapy: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><year>2021</year><volume>4</volume><issue>8</issue><fpage>e2118895</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.18895</pub-id><pub-id pub-id-type="pmid">34338793</pub-id><pub-id pub-id-type="pmcid">PMC8329743</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Chen CH, Huang CY, Lin HH, Wang MC, Chang CY, Cheng YF. Association of sodium thiosulfate with risk of ototoxic effects from platinum-based chemotherapy: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(8): e2118895.<pub-id pub-id-type="pmid">34338793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.18895</pub-id><pub-id pub-id-type="pmcid">PMC8329743</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Summers</surname><given-names>C</given-names></name><name name-style="western"><surname>Rankin</surname><given-names>SM</given-names></name><name name-style="western"><surname>Condliffe</surname><given-names>AM</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N</given-names></name><name name-style="western"><surname>Peters</surname><given-names>AM</given-names></name><name name-style="western"><surname>Chilvers</surname><given-names>ER</given-names></name></person-group><article-title>Neutrophil kinetics in health and disease</article-title><source>Trends Immunol</source><year>2010</year><volume>31</volume><issue>8</issue><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.it.2010.05.006</pub-id><pub-id pub-id-type="pmid">20620114</pub-id><pub-id pub-id-type="pmcid">PMC2930213</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol. 2010;31(8):318&#8211;24.<pub-id pub-id-type="pmid">20620114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.it.2010.05.006</pub-id><pub-id pub-id-type="pmcid">PMC2930213</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kloft</surname><given-names>C</given-names></name><name name-style="western"><surname>Wallin</surname><given-names>J</given-names></name><name name-style="western"><surname>Henningsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><issue>18</issue><fpage>5481</fpage><lpage>5490</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0815</pub-id><pub-id pub-id-type="pmid">17000683</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12(18):5481&#8211;90.<pub-id pub-id-type="pmid">17000683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-06-0815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Wu YH, Chen HY, Hong WC, Wei CY, Pang JS. Carboplatin-induced thrombocytopenia through JAK2 downregulation, S-phase cell cycle arrest and apoptosis in megakaryocytes. Int J Mol Sci. 2022;23(11).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23116290</pub-id><pub-id pub-id-type="pmcid">PMC9181531</pub-id><pub-id pub-id-type="pmid">35682967</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name><name name-style="western"><surname>Zeltsman</surname><given-names>M</given-names></name><name name-style="western"><surname>Zauderer</surname><given-names>MG</given-names></name><name name-style="western"><surname>Eguchi</surname><given-names>T</given-names></name><name name-style="western"><surname>Vaghjiani</surname><given-names>RG</given-names></name><name name-style="western"><surname>Adusumilli</surname><given-names>PS</given-names></name></person-group><article-title>Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy</article-title><source>Immunotherapy</source><year>2017</year><volume>9</volume><issue>11</issue><fpage>913</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.2217/imt-2017-0052</pub-id><pub-id pub-id-type="pmid">29338609</pub-id><pub-id pub-id-type="pmcid">PMC5810850</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017;9(11):913&#8211;27.<pub-id pub-id-type="pmid">29338609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt-2017-0052</pub-id><pub-id pub-id-type="pmcid">PMC5810850</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Cui</surname><given-names>G</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>870178</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.870178</pub-id><pub-id pub-id-type="pmid">35784745</pub-id><pub-id pub-id-type="pmcid">PMC9240830</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Zhou Z, Zhao Y, Chen S, Cui G, Fu W, Li S, et al. Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils. Front Pharmacol. 2022;13: 870178.<pub-id pub-id-type="pmid">35784745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.870178</pub-id><pub-id pub-id-type="pmcid">PMC9240830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Low-dose carboplatin reprograms tumour immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer</article-title><source>Cancer Lett</source><year>2021</year><volume>500</volume><fpage>163</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.11.049</pub-id><pub-id pub-id-type="pmid">33278498</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zhou L, Xu Q, Huang L, Jin J, Zuo X, Zhang Q, et al. Low-dose carboplatin reprograms tumour immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 2021;500:163&#8211;71.<pub-id pub-id-type="pmid">33278498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2020.11.049</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alderden</surname><given-names>RA</given-names></name><name name-style="western"><surname>Hall</surname><given-names>MD</given-names></name><name name-style="western"><surname>Hambley</surname><given-names>TW</given-names></name></person-group><article-title>The discovery and development of cisplatin</article-title><source>J Chem Educ</source><year>2006</year><volume>83</volume><issue>5</issue><fpage>728</fpage><pub-id pub-id-type="doi">10.1021/ed083p728</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educ. 2006;83(5):728.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Planting</surname><given-names>AS</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>ME</given-names></name><name name-style="western"><surname>van Meerten</surname><given-names>E</given-names></name><name name-style="western"><surname>de Boer-Dennert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours</article-title><source>Br J Cancer</source><year>1996</year><volume>73</volume><issue>12</issue><fpage>1569</fpage><lpage>1575</lpage><pub-id pub-id-type="doi">10.1038/bjc.1996.296</pub-id><pub-id pub-id-type="pmid">8664132</pub-id><pub-id pub-id-type="pmcid">PMC2074557</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer. 1996;73(12):1569&#8211;75.<pub-id pub-id-type="pmid">8664132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.1996.296</pub-id><pub-id pub-id-type="pmcid">PMC2074557</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trendowski</surname><given-names>MR</given-names></name><name name-style="western"><surname>El Charif</surname><given-names>O</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>PC</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Travis</surname><given-names>LB</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>ME</given-names></name></person-group><article-title>Genetic and modifiable risk factors contributing to cisplatin-induced toxicities</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>4</issue><fpage>1147</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2244</pub-id><pub-id pub-id-type="pmid">30305294</pub-id><pub-id pub-id-type="pmcid">PMC6377815</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. 2019;25(4):1147&#8211;55.<pub-id pub-id-type="pmid">30305294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-18-2244</pub-id><pub-id pub-id-type="pmcid">PMC6377815</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>ME</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>SL</given-names></name><name name-style="western"><surname>Mercke</surname><given-names>N</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients</article-title><source>Eur J Clin Pharmacol</source><year>2019</year><volume>75</volume><issue>1</issue><fpage>51</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1007/s00228-018-2552-z</pub-id><pub-id pub-id-type="pmid">30220072</pub-id><pub-id pub-id-type="pmcid">PMC6656531</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, et al. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019;75(1):51&#8211;7.<pub-id pub-id-type="pmid">30220072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-018-2552-z</pub-id><pub-id pub-id-type="pmcid">PMC6656531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crona</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Faso</surname><given-names>A</given-names></name><name name-style="western"><surname>Nishijima</surname><given-names>TF</given-names></name><name name-style="western"><surname>McGraw</surname><given-names>KA</given-names></name><name name-style="western"><surname>Galsky</surname><given-names>MD</given-names></name><name name-style="western"><surname>Milowsky</surname><given-names>MI</given-names></name></person-group><article-title>A systematic review of strategies to prevent cisplatin-induced nephrotoxicity</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><issue>5</issue><fpage>609</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0319</pub-id><pub-id pub-id-type="pmid">28438887</pub-id><pub-id pub-id-type="pmcid">PMC5423518</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22(5):609&#8211;19.<pub-id pub-id-type="pmid">28438887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1634/theoncologist.2016-0319</pub-id><pub-id pub-id-type="pmcid">PMC5423518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Staff</surname><given-names>NP</given-names></name><name name-style="western"><surname>Grisold</surname><given-names>A</given-names></name><name name-style="western"><surname>Grisold</surname><given-names>W</given-names></name><name name-style="western"><surname>Windebank</surname><given-names>AJ</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neuropathy: a current review</article-title><source>Ann Neurol</source><year>2017</year><volume>81</volume><issue>6</issue><fpage>772</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1002/ana.24951</pub-id><pub-id pub-id-type="pmid">28486769</pub-id><pub-id pub-id-type="pmcid">PMC5656281</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772&#8211;81.<pub-id pub-id-type="pmid">28486769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24951</pub-id><pub-id pub-id-type="pmcid">PMC5656281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name><name name-style="western"><surname>White-Koning</surname><given-names>ML</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RH</given-names></name><name name-style="western"><surname>Puisset</surname><given-names>F</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SD</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name></person-group><article-title>Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents</article-title><source>Br J Cancer</source><year>2012</year><volume>107</volume><issue>7</issue><fpage>1100</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.357</pub-id><pub-id pub-id-type="pmid">22929884</pub-id><pub-id pub-id-type="pmcid">PMC3461153</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer. 2012;107(7):1100&#8211;6.<pub-id pub-id-type="pmid">22929884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bjc.2012.357</pub-id><pub-id pub-id-type="pmcid">PMC3461153</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">ADDIKD. International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction. Sandhu G, Adattini J, Armstrong Gordon E, O&#8217;Neill N. on behalf of the ADDIKD Guideline Working Group. 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction">https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction</ext-link>. Accessed 03 Feb 2025.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2025.103161</pub-id><pub-id pub-id-type="pmcid">PMC12034076</pub-id><pub-id pub-id-type="pmid">40290844</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennis</surname><given-names>Y</given-names></name><name name-style="western"><surname>Savry</surname><given-names>A</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>M</given-names></name><name name-style="western"><surname>Gauthier-Villano</surname><given-names>L</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>P</given-names></name><name name-style="western"><surname>Pourroy</surname><given-names>B</given-names></name></person-group><article-title>Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?</article-title><source>Int J Clin Pharm</source><year>2014</year><volume>36</volume><issue>2</issue><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1007/s11096-013-9912-7</pub-id><pub-id pub-id-type="pmid">24435159</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Bennis Y, Savry A, Rocca M, Gauthier-Villano L, Pisano P, Pourroy B. Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int J Clin Pharm. 2014;36(2):420&#8211;9.<pub-id pub-id-type="pmid">24435159</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11096-013-9912-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murakami</surname><given-names>T</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ide</surname><given-names>H</given-names></name><name name-style="western"><surname>Umezawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Izawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma</article-title><source>BJUI Compass.</source><year>2021</year><volume>2</volume><issue>5</issue><fpage>322</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1002/bco2.81</pub-id><pub-id pub-id-type="pmid">35474877</pub-id><pub-id pub-id-type="pmcid">PMC8988766</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Murakami T, Kikuchi E, Ide H, Umezawa Y, Takahashi T, Izawa M, et al. Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma. BJUI Compass. 2021;2(5):322&#8211;30.<pub-id pub-id-type="pmid">35474877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/bco2.81</pub-id><pub-id pub-id-type="pmcid">PMC8988766</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dr&#246;gem&#246;ller</surname><given-names>BI</given-names></name><name name-style="western"><surname>Wright</surname><given-names>GEB</given-names></name><name name-style="western"><surname>Lo</surname><given-names>C</given-names></name><name name-style="western"><surname>Le</surname><given-names>T</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>B</given-names></name><name name-style="western"><surname>Bhavsar</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Pharmacogenomics of cisplatin-induced ototoxicity: successes, shortcomings, and future avenues of research</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>106</volume><issue>2</issue><fpage>350</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1002/cpt.1483</pub-id><pub-id pub-id-type="pmid">31012503</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Dr&#246;gem&#246;ller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, et al. Pharmacogenomics of cisplatin-induced ototoxicity: successes, shortcomings, and future avenues of research. Clin Pharmacol Ther. 2019;106(2):350&#8211;9.<pub-id pub-id-type="pmid">31012503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1483</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zazuli</surname><given-names>Z</given-names></name><name name-style="western"><surname>Vijverberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Slob</surname><given-names>E</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Carleton</surname><given-names>B</given-names></name><name name-style="western"><surname>Veltman</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genetic variations and cisplatin nephrotoxicity: a systematic review</article-title><source>Front Pharmacol</source><year>2018</year><volume>9</volume><fpage>1111</fpage><pub-id pub-id-type="doi">10.3389/fphar.2018.01111</pub-id><pub-id pub-id-type="pmid">30319427</pub-id><pub-id pub-id-type="pmcid">PMC6171472</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J, et al. Genetic variations and cisplatin nephrotoxicity: a systematic review. Front Pharmacol. 2018;9:1111.<pub-id pub-id-type="pmid">30319427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.01111</pub-id><pub-id pub-id-type="pmcid">PMC6171472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Zazuli Z, de Jong C, Xu W, Vijverberg SJH, Masereeuw R, Patel D, et al. Association between genetic variants and cisplatin-induced nephrotoxicity: a genome-wide approach and validation study. J Pers Med. 2021;11(11).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jpm11111233</pub-id><pub-id pub-id-type="pmcid">PMC8623115</pub-id><pub-id pub-id-type="pmid">34834585</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Maio</surname><given-names>M</given-names></name><name name-style="western"><surname>Gridelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>C</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>F</given-names></name><name name-style="western"><surname>Piantedosi</surname><given-names>FV</given-names></name><name name-style="western"><surname>Cigolari</surname><given-names>S</given-names></name><etal/></person-group><article-title>Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials</article-title><source>Lancet Oncol</source><year>2005</year><volume>6</volume><issue>9</issue><fpage>669</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(05)70255-2</pub-id><pub-id pub-id-type="pmid">16129367</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6(9):669&#8211;77.<pub-id pub-id-type="pmid">16129367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(05)70255-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maillard</surname><given-names>M</given-names></name><name name-style="western"><surname>Le Louedec</surname><given-names>F</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>F</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name></person-group><article-title>Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2020</year><volume>16</volume><issue>10</issue><fpage>907</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1080/17425255.2020.1789590</pub-id><pub-id pub-id-type="pmid">33016786</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Maillard M, Le Louedec F, Thomas F, Chatelut E. Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. Expert Opin Drug Metab Toxicol. 2020;16(10):907&#8211;25.<pub-id pub-id-type="pmid">33016786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17425255.2020.1789590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monjanel-Mouterde</surname><given-names>S</given-names></name><name name-style="western"><surname>Ciccolini</surname><given-names>J</given-names></name><name name-style="western"><surname>Bagarry</surname><given-names>D</given-names></name><name name-style="western"><surname>Zonta-David</surname><given-names>M</given-names></name><name name-style="western"><surname>Duffaud</surname><given-names>F</given-names></name><name name-style="western"><surname>Favre</surname><given-names>R</given-names></name><name name-style="western"><surname>Durand</surname><given-names>A</given-names></name></person-group><article-title>Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback</article-title><source>J Clin Pharm Ther</source><year>2003</year><volume>28</volume><issue>2</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2710.2003.00468.x</pub-id><pub-id pub-id-type="pmid">12713607</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Monjanel-Mouterde S, Ciccolini J, Bagarry D, Zonta-David M, Duffaud F, Favre R, Durand A. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. J Clin Pharm Ther. 2003;28(2):109&#8211;16.<pub-id pub-id-type="pmid">12713607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2710.2003.00468.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salas</surname><given-names>S</given-names></name><name name-style="western"><surname>Mercier</surname><given-names>C</given-names></name><name name-style="western"><surname>Ciccolini</surname><given-names>J</given-names></name><name name-style="western"><surname>Pourroy</surname><given-names>B</given-names></name><name name-style="western"><surname>Fanciullino</surname><given-names>R</given-names></name><name name-style="western"><surname>Tranchand</surname><given-names>B</given-names></name><etal/></person-group><article-title>Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma</article-title><source>Ther Drug Monit</source><year>2006</year><volume>28</volume><issue>4</issue><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1097/00007691-200608000-00008</pub-id><pub-id pub-id-type="pmid">16885721</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, et al. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit. 2006;28(4):532&#8211;9.<pub-id pub-id-type="pmid">16885721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-200608000-00008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Von Hoff</surname><given-names>DD</given-names></name></person-group><article-title>Whither carboplatin?&#8212;a replacement for or an alternative to cisplatin?</article-title><source>J Clin Oncol</source><year>1987</year><volume>5</volume><issue>2</issue><fpage>169</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1200/JCO.1987.5.2.169</pub-id><pub-id pub-id-type="pmid">3543240</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Von Hoff DD. Whither carboplatin?&#8212;a replacement for or an alternative to cisplatin? J Clin Oncol. 1987;5(2):169&#8211;71.<pub-id pub-id-type="pmid">3543240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1987.5.2.169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">FDA. Food and Drug Administration - Carboplatin injection - Product information. 2011. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/077139Orig1s016lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/077139Orig1s016lbl.pdf</ext-link>. Accessed 05 Dec 2024.</mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calvert</surname><given-names>AH</given-names></name><name name-style="western"><surname>Newell</surname><given-names>DR</given-names></name><name name-style="western"><surname>Gumbrell</surname><given-names>LA</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>S</given-names></name><name name-style="western"><surname>Burnell</surname><given-names>M</given-names></name><name name-style="western"><surname>Boxall</surname><given-names>FE</given-names></name><etal/></person-group><article-title>Carboplatin dosage: prospective evaluation of a simple formula based on renal function</article-title><source>J Clin Oncol</source><year>1989</year><volume>7</volume><issue>11</issue><fpage>1748</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1200/JCO.1989.7.11.1748</pub-id><pub-id pub-id-type="pmid">2681557</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Calvert AH, Newell DR, Gumbrell LA, O&#8217;Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748&#8211;56.<pub-id pub-id-type="pmid">2681557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1989.7.11.1748</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985;12 Suppl A:67&#8211;71.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0305-7372(85)90020-9</pub-id><pub-id pub-id-type="pmid">3910224</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name><name name-style="western"><surname>Greene</surname><given-names>T</given-names></name><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Assessing kidney function-measured and estimated glomerular filtration rate</article-title><source>N Engl J Med</source><year>2006</year><volume>354</volume><issue>23</issue><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1056/NEJMra054415</pub-id><pub-id pub-id-type="pmid">16760447</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473&#8211;83.<pub-id pub-id-type="pmid">16760447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra054415</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cockcroft</surname><given-names>DW</given-names></name><name name-style="western"><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><issue>1</issue><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1159/000180580</pub-id><pub-id pub-id-type="pmid">1244564</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31&#8211;41.<pub-id pub-id-type="pmid">1244564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000180580</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekhart</surname><given-names>C</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>ME</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>AD</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name><name name-style="western"><surname>Rodenhuis</surname><given-names>S</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name></person-group><article-title>Flat dosing of carboplatin is justified in adult patients with normal renal function</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><issue>21</issue><fpage>6502</fpage><lpage>6508</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1076</pub-id><pub-id pub-id-type="pmid">17085665</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res. 2006;12(21):6502&#8211;8.<pub-id pub-id-type="pmid">17085665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-05-1076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Rosa</surname><given-names>S</given-names></name><name name-style="western"><surname>Greco</surname><given-names>M</given-names></name><name name-style="western"><surname>Rauseo</surname><given-names>M</given-names></name><name name-style="western"><surname>Annetta</surname><given-names>MG</given-names></name></person-group><article-title>The good, the bad, and the serum creatinine: exploring the effect of muscle mass and nutrition</article-title><source>Blood Purif</source><year>2023</year><volume>52</volume><issue>9&#8211;10</issue><fpage>775</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1159/000533173</pub-id><pub-id pub-id-type="pmid">37742621</pub-id><pub-id pub-id-type="pmcid">PMC10623400</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">De Rosa S, Greco M, Rauseo M, Annetta MG. The good, the bad, and the serum creatinine: exploring the effect of muscle mass and nutrition. Blood Purif. 2023;52(9&#8211;10):775&#8211;85.<pub-id pub-id-type="pmid">37742621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000533173</pub-id><pub-id pub-id-type="pmcid">PMC10623400</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bretagne</surname><given-names>M</given-names></name><name name-style="western"><surname>Jouinot</surname><given-names>A</given-names></name><name name-style="western"><surname>Durand</surname><given-names>JP</given-names></name><name name-style="western"><surname>Huillard</surname><given-names>O</given-names></name><name name-style="western"><surname>Boudou Rouquette</surname><given-names>P</given-names></name><name name-style="western"><surname>Tlemsani</surname><given-names>C</given-names></name><etal/></person-group><article-title>Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity</article-title><source>Cancer Chemother Pharmacol</source><year>2017</year><volume>80</volume><issue>1</issue><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1007/s00280-017-3326-5</pub-id><pub-id pub-id-type="pmid">28508095</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Bretagne M, Jouinot A, Durand JP, Huillard O, Boudou Rouquette P, Tlemsani C, et al. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chemother Pharmacol. 2017;80(1):45&#8211;53.<pub-id pub-id-type="pmid">28508095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-017-3326-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrington</surname><given-names>JD</given-names></name><name name-style="western"><surname>Tran</surname><given-names>HT</given-names></name><name name-style="western"><surname>Riggs</surname><given-names>MW</given-names></name></person-group><article-title>Prospective evaluation of carboplatin AUC dosing in patients with a BMI&gt;or=27 or cachexia</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>57</volume><issue>2</issue><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1007/s00280-005-0012-9</pub-id><pub-id pub-id-type="pmid">16133538</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI&gt;or=27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241&#8211;7.<pub-id pub-id-type="pmid">16133538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-005-0012-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millward</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Webster</surname><given-names>LK</given-names></name><name name-style="western"><surname>Toner</surname><given-names>GC</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>JF</given-names></name><name name-style="western"><surname>Rischin</surname><given-names>D</given-names></name><name name-style="western"><surname>Stokes</surname><given-names>KH</given-names></name><etal/></person-group><article-title>Carboplatin dosing based on measurement of renal function&#8211;experience at the Peter MacCallum Cancer Institute</article-title><source>Aust N Z J Med</source><year>1996</year><volume>26</volume><issue>3</issue><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1111/j.1445-5994.1996.tb01925.x</pub-id><pub-id pub-id-type="pmid">8811211</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, et al. Carboplatin dosing based on measurement of renal function&#8211;experience at the Peter MacCallum Cancer Institute. Aust N Z J Med. 1996;26(3):372&#8211;9.<pub-id pub-id-type="pmid">8811211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1445-5994.1996.tb01925.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picton</surname><given-names>SV</given-names></name><name name-style="western"><surname>Keeble</surname><given-names>J</given-names></name><name name-style="western"><surname>Holden</surname><given-names>V</given-names></name><name name-style="western"><surname>Errington</surname><given-names>J</given-names></name><name name-style="western"><surname>Boddy</surname><given-names>AV</given-names></name><name name-style="western"><surname>Veal</surname><given-names>GJ</given-names></name></person-group><article-title>Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma</article-title><source>Cancer Chemother Pharmacol</source><year>2009</year><volume>63</volume><issue>4</issue><fpage>749</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1007/s00280-008-0787-6</pub-id><pub-id pub-id-type="pmid">18607591</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Picton SV, Keeble J, Holden V, Errington J, Boddy AV, Veal GJ. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol. 2009;63(4):749&#8211;52.<pub-id pub-id-type="pmid">18607591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-008-0787-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veal</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Errington</surname><given-names>J</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>J</given-names></name><name name-style="western"><surname>Hobin</surname><given-names>D</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>D</given-names></name><name name-style="western"><surname>Dommett</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Carboplatin therapeutic monitoring in preterm and full-term neonates</article-title><source>Eur J Cancer</source><year>2015</year><volume>51</volume><issue>14</issue><fpage>2022</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2015.07.011</pub-id><pub-id pub-id-type="pmid">26232270</pub-id><pub-id pub-id-type="pmcid">PMC4571926</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51(14):2022&#8211;30.<pub-id pub-id-type="pmid">26232270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2015.07.011</pub-id><pub-id pub-id-type="pmcid">PMC4571926</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moeung</surname><given-names>S</given-names></name><name name-style="western"><surname>Chevreau</surname><given-names>C</given-names></name><name name-style="western"><surname>Broutin</surname><given-names>S</given-names></name><name name-style="western"><surname>Guitton</surname><given-names>J</given-names></name><name name-style="western"><surname>Leli&#232;vre</surname><given-names>B</given-names></name><name name-style="western"><surname>Ciccolini</surname><given-names>J</given-names></name><etal/></person-group><article-title>Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumours: pharmacokinetic results of a phase II multicenter study</article-title><source>Clin Cancer Res</source><year>2017</year><volume>23</volume><issue>23</issue><fpage>7171</fpage><lpage>7179</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1344</pub-id><pub-id pub-id-type="pmid">28928162</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Moeung S, Chevreau C, Broutin S, Guitton J, Leli&#232;vre B, Ciccolini J, et al. Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumours: pharmacokinetic results of a phase II multicenter study. Clin Cancer Res. 2017;23(23):7171&#8211;9.<pub-id pub-id-type="pmid">28928162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-17-1344</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Bozec</surname><given-names>A</given-names></name><name name-style="western"><surname>Boulanger</surname><given-names>C</given-names></name><name name-style="western"><surname>Mongaret</surname><given-names>C</given-names></name><name name-style="western"><surname>Mar&#233;chal</surname><given-names>A</given-names></name><name name-style="western"><surname>Dewolf</surname><given-names>M</given-names></name><name name-style="western"><surname>Slimano</surname><given-names>F</given-names></name></person-group><article-title>Safety and survival outcomes in lung cancer patients receiving carboplatin: impact of uncapped dosage</article-title><source>Chemotherapy</source><year>2021</year><volume>66</volume><issue>3</issue><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1159/000516170</pub-id><pub-id pub-id-type="pmid">34280922</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Le Bozec A, Boulanger C, Mongaret C, Mar&#233;chal A, Dewolf M, Slimano F. Safety and survival outcomes in lung cancer patients receiving carboplatin: impact of uncapped dosage. Chemotherapy. 2021;66(3):72&#8211;7.<pub-id pub-id-type="pmid">34280922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000516170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>A</given-names></name><name name-style="western"><surname>Gladieff</surname><given-names>L</given-names></name><name name-style="western"><surname>Laffont</surname><given-names>CM</given-names></name><name name-style="western"><surname>Evrard</surname><given-names>A</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>J-C</given-names></name><name name-style="western"><surname>Lansiaux</surname><given-names>A</given-names></name><etal/></person-group><article-title>Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>30</issue><fpage>4568</fpage><lpage>4574</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.29.3597</pub-id><pub-id pub-id-type="pmid">20855828</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer J-C, Lansiaux A, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28(30):4568&#8211;74.<pub-id pub-id-type="pmid">20855828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2010.29.3597</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ackermans</surname><given-names>L</given-names></name><name name-style="western"><surname>Volmer</surname><given-names>L</given-names></name><name name-style="western"><surname>Timmermans</surname><given-names>Q</given-names></name><name name-style="western"><surname>Brecheisen</surname><given-names>R</given-names></name><name name-style="western"><surname>Damink</surname><given-names>S</given-names></name><name name-style="western"><surname>Dekker</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical evaluation of automated segmentation for body composition analysis on abdominal L3 CT slices in polytrauma patients</article-title><source>Injury</source><year>2022</year><volume>53</volume><issue>Suppl 3</issue><fpage>S30</fpage><lpage>s41</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2022.05.004</pub-id><pub-id pub-id-type="pmid">35680433</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Ackermans L, Volmer L, Timmermans Q, Brecheisen R, Damink S, Dekker A, et al. Clinical evaluation of automated segmentation for body composition analysis on abdominal L3 CT slices in polytrauma patients. Injury. 2022;53(Suppl 3):S30-s41.<pub-id pub-id-type="pmid">35680433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.injury.2022.05.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pieters</surname><given-names>TT</given-names></name><name name-style="western"><surname>Veldhuis</surname><given-names>WB</given-names></name><name name-style="western"><surname>Moeskops</surname><given-names>P</given-names></name><name name-style="western"><surname>de Vos</surname><given-names>BD</given-names></name><name name-style="western"><surname>Verhaar</surname><given-names>MC</given-names></name><name name-style="western"><surname>Haitjema</surname><given-names>S</given-names></name><etal/></person-group><article-title>Deep learning body-composition analysis of clinically acquired CT-scans estimates creatinine excretion with high accuracy in patients and healthy individuals</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>9013</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-13145-w</pub-id><pub-id pub-id-type="pmid">35637278</pub-id><pub-id pub-id-type="pmcid">PMC9151677</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Pieters TT, Veldhuis WB, Moeskops P, de Vos BD, Verhaar MC, Haitjema S, et al. Deep learning body-composition analysis of clinically acquired CT-scans estimates creatinine excretion with high accuracy in patients and healthy individuals. Sci Rep. 2022;12(1):9013.<pub-id pub-id-type="pmid">35637278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-13145-w</pub-id><pub-id pub-id-type="pmcid">PMC9151677</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beunders</surname><given-names>R</given-names></name><name name-style="western"><surname>van Groenendael</surname><given-names>R</given-names></name><name name-style="western"><surname>Leijte</surname><given-names>GP</given-names></name><name name-style="western"><surname>Kox</surname><given-names>M</given-names></name><name name-style="western"><surname>Pickkers</surname><given-names>P</given-names></name></person-group><article-title>Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients</article-title><source>Shock</source><year>2020</year><volume>54</volume><issue>3</issue><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000001510</pub-id><pub-id pub-id-type="pmid">31977957</pub-id><pub-id pub-id-type="pmcid">PMC7458088</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Beunders R, van Groenendael R, Leijte GP, Kox M, Pickkers P. Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients. Shock. 2020;54(3):308&#8211;14.<pub-id pub-id-type="pmid">31977957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000001510</pub-id><pub-id pub-id-type="pmcid">PMC7458088</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inker</surname><given-names>LA</given-names></name><name name-style="western"><surname>Eneanya</surname><given-names>ND</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name><name name-style="western"><surname>Tighiouart</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>New creatinine- and cystatin c-based equations to estimate GFR without race</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><issue>19</issue><fpage>1737</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737&#8211;49.<pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitt</surname><given-names>A</given-names></name><name name-style="western"><surname>Gladieff</surname><given-names>L</given-names></name><name name-style="western"><surname>Lansiaux</surname><given-names>A</given-names></name><name name-style="western"><surname>Bobin-Dubigeon</surname><given-names>C</given-names></name><name name-style="western"><surname>Etienne-Grimaldi</surname><given-names>MC</given-names></name><name name-style="western"><surname>Boisdron-Celle</surname><given-names>M</given-names></name><etal/></person-group><article-title>A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><issue>10</issue><fpage>3633</fpage><lpage>3639</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0017</pub-id><pub-id pub-id-type="pmid">19401344</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res. 2009;15(10):3633&#8211;9.<pub-id pub-id-type="pmid">19401344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-09-0017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>F</given-names></name><name name-style="western"><surname>S&#233;ronie-Vivien</surname><given-names>S</given-names></name><name name-style="western"><surname>Gladieff</surname><given-names>L</given-names></name><name name-style="western"><surname>Dalenc</surname><given-names>F</given-names></name><name name-style="western"><surname>Durrand</surname><given-names>V</given-names></name><name name-style="western"><surname>Malard</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><issue>12</issue><fpage>1305</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.2165/00003088-200544120-00009</pub-id><pub-id pub-id-type="pmid">16372828</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Thomas F, S&#233;ronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, et al. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet. 2005;44(12):1305&#8211;16.<pub-id pub-id-type="pmid">16372828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200544120-00009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White-Koning</surname><given-names>M</given-names></name><name name-style="western"><surname>Paludetto</surname><given-names>MN</given-names></name><name name-style="western"><surname>Le Louedec</surname><given-names>F</given-names></name><name name-style="western"><surname>Gladieff</surname><given-names>L</given-names></name><name name-style="western"><surname>Chevreau</surname><given-names>C</given-names></name><name name-style="western"><surname>Chatelut</surname><given-names>E</given-names></name><name name-style="western"><surname>Puisset</surname><given-names>F</given-names></name></person-group><article-title>Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance</article-title><source>Cancer Chemother Pharmacol</source><year>2020</year><volume>85</volume><issue>3</issue><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1007/s00280-019-04020-z</pub-id><pub-id pub-id-type="pmid">31915969</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">White-Koning M, Paludetto MN, Le Louedec F, Gladieff L, Chevreau C, Chatelut E, Puisset F. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance. Cancer Chemother Pharmacol. 2020;85(3):585&#8211;92.<pub-id pub-id-type="pmid">31915969</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-019-04020-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#248;rensen</surname><given-names>JB</given-names></name></person-group><article-title>Pharmacokinetic evaluation of pemetrexed</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2011</year><volume>7</volume><issue>7</issue><fpage>919</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1517/17425255.2011.587411</pub-id><pub-id pub-id-type="pmid">21599552</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">S&#248;rensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol. 2011;7(7):919&#8211;28.<pub-id pub-id-type="pmid">21599552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2011.587411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shih</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Gossett</surname><given-names>LS</given-names></name><name name-style="western"><surname>Gates</surname><given-names>SB</given-names></name><name name-style="western"><surname>MacKellar</surname><given-names>WC</given-names></name><name name-style="western"><surname>Habeck</surname><given-names>LL</given-names></name><etal/></person-group><article-title>LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes</article-title><source>Cancer Res</source><year>1997</year><volume>57</volume><issue>6</issue><fpage>1116</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">9067281</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57(6):1116&#8211;23.<pub-id pub-id-type="pmid">9067281</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Lu CS, Lin CW, Chang YH, Chen HY, Chung WC, Lai WY, et al. Antimetabolite pemetrexed primes a favorable tumour microenvironment for immune checkpoint blockade therapy. J Immunother Cancer. 2020;8(2).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2020-001392</pub-id><pub-id pub-id-type="pmcid">PMC7692992</pub-id><pub-id pub-id-type="pmid">33243934</pub-id></mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>L</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>E</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><issue>22</issue><fpage>2078</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1801005</pub-id><pub-id pub-id-type="pmid">29658856</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Gandhi L, Rodr&#237;guez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078&#8211;92.<pub-id pub-id-type="pmid">29658856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1801005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishio</surname><given-names>M</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F</given-names></name><name name-style="western"><surname>West</surname><given-names>H</given-names></name><name name-style="western"><surname>Ball</surname><given-names>S</given-names></name><name name-style="western"><surname>Bordoni</surname><given-names>R</given-names></name><name name-style="western"><surname>Cobo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><issue>4</issue><fpage>653</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.11.025</pub-id><pub-id pub-id-type="pmid">33333328</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021;16(4):653&#8211;64.<pub-id pub-id-type="pmid">33333328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2020.11.025</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latz</surname><given-names>JE</given-names></name><name name-style="western"><surname>Chaudhary</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>RD</given-names></name></person-group><article-title>Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>57</volume><issue>4</issue><fpage>401</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1007/s00280-005-0036-1</pub-id><pub-id pub-id-type="pmid">16322991</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol. 2006;57(4):401&#8211;11.<pub-id pub-id-type="pmid">16322991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-005-0036-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Murai</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>H</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of renal function on pemetrexed-induced haematotoxicity</article-title><source>Cancer Chemother Pharmacol</source><year>2016</year><volume>78</volume><issue>1</issue><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3078-7</pub-id><pub-id pub-id-type="pmid">27286996</pub-id><pub-id pub-id-type="pmcid">PMC4921104</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, et al. Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol. 2016;78(1):183&#8211;9.<pub-id pub-id-type="pmid">27286996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-016-3078-7</pub-id><pub-id pub-id-type="pmcid">PMC4921104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latz</surname><given-names>JE</given-names></name><name name-style="western"><surname>Rusthoven</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>RD</given-names></name></person-group><article-title>Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>57</volume><issue>4</issue><fpage>427</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1007/s00280-005-0035-2</pub-id><pub-id pub-id-type="pmid">16322992</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57(4):427&#8211;35.<pub-id pub-id-type="pmid">16322992</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-005-0035-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><mixed-citation publication-type="other">FDA. Food and Drug Administration - ALIMTA (pemetrexed disodium) Injection - Product information. 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf</ext-link>. Accessed 05 Dec 2024.</mixed-citation></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Abratt</surname><given-names>R</given-names></name><name name-style="western"><surname>Goedhals</surname><given-names>L</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Millward</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ackland</surname><given-names>SP</given-names></name></person-group><article-title>Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na&#239;ve patients with advanced non-small-cell lung cancer</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><issue>5</issue><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdf115</pub-id><pub-id pub-id-type="pmid">12075742</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na&#239;ve patients with advanced non-small-cell lung cancer. Ann Oncol. 2002;13(5):737&#8211;41.<pub-id pub-id-type="pmid">12075742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdf115</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><mixed-citation publication-type="other">Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17(4):1194.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1999.17.4.1194</pub-id><pub-id pub-id-type="pmid">10561178</pub-id></mixed-citation></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crawford</surname><given-names>J</given-names></name><name name-style="western"><surname>Dale</surname><given-names>DC</given-names></name><name name-style="western"><surname>Lyman</surname><given-names>GH</given-names></name></person-group><article-title>Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management</article-title><source>Cancer</source><year>2004</year><volume>100</volume><issue>2</issue><fpage>228</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1002/cncr.11882</pub-id><pub-id pub-id-type="pmid">14716755</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228&#8211;37.<pub-id pub-id-type="pmid">14716755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.11882</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niyikiza</surname><given-names>C</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SD</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>DE</given-names></name><name name-style="western"><surname>Walling</surname><given-names>JM</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>K</given-names></name><name name-style="western"><surname>Rusthoven</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy</article-title><source>Mol Cancer Ther</source><year>2002</year><volume>1</volume><issue>7</issue><fpage>545</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">12479273</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1(7):545&#8211;52.<pub-id pub-id-type="pmid">12479273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paz-Ares</surname><given-names>LG</given-names></name><name name-style="western"><surname>de Marinis</surname><given-names>F</given-names></name><name name-style="western"><surname>Dediu</surname><given-names>M</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M</given-names></name><name name-style="western"><surname>Pujol</surname><given-names>JL</given-names></name><name name-style="western"><surname>Bidoli</surname><given-names>P</given-names></name><etal/></person-group><article-title>PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>23</issue><fpage>2895</fpage><lpage>2902</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.47.1102</pub-id><pub-id pub-id-type="pmid">23835707</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895&#8211;902.<pub-id pub-id-type="pmid">23835707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.47.1102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visser</surname><given-names>S</given-names></name><name name-style="western"><surname>Koolen</surname><given-names>SLW</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>P</given-names></name><name name-style="western"><surname>Belderbos</surname><given-names>HNA</given-names></name><name name-style="western"><surname>Cornelissen</surname><given-names>R</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RHJ</given-names></name><etal/></person-group><article-title>Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study</article-title><source>Eur J Cancer</source><year>2019</year><volume>121</volume><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2019.08.012</pub-id><pub-id pub-id-type="pmid">31561135</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Visser S, Koolen SLW, de Bruijn P, Belderbos HNA, Cornelissen R, Mathijssen RHJ, et al. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study. Eur J Cancer. 2019;121:64&#8211;73.<pub-id pub-id-type="pmid">31561135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2019.08.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boosman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Dorlo</surname><given-names>TPC</given-names></name><name name-style="western"><surname>de Rouw</surname><given-names>N</given-names></name><name name-style="western"><surname>Burgers</surname><given-names>JA</given-names></name><name name-style="western"><surname>Dingemans</surname><given-names>AC</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment</article-title><source>Int J Cancer</source><year>2021</year><volume>149</volume><issue>8</issue><fpage>1576</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1002/ijc.33721</pub-id><pub-id pub-id-type="pmid">34181276</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AC, van den Heuvel MM, et al. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. Int J Cancer. 2021;149(8):1576&#8211;84.<pub-id pub-id-type="pmid">34181276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.33721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoller</surname><given-names>RG</given-names></name><name name-style="western"><surname>Hande</surname><given-names>KR</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>SA</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>SA</given-names></name><name name-style="western"><surname>Chabner</surname><given-names>BA</given-names></name></person-group><article-title>Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity</article-title><source>N Engl J Med</source><year>1977</year><volume>297</volume><issue>12</issue><fpage>630</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1056/NEJM197709222971203</pub-id><pub-id pub-id-type="pmid">302412</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297(12):630&#8211;4.<pub-id pub-id-type="pmid">302412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM197709222971203</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>G</given-names></name><name name-style="western"><surname>Gridelli</surname><given-names>C</given-names></name><name name-style="western"><surname>De Marinis</surname><given-names>F</given-names></name><name name-style="western"><surname>Pujol</surname><given-names>JL</given-names></name><name name-style="western"><surname>Reck</surname><given-names>M</given-names></name><name name-style="western"><surname>Ramlau</surname><given-names>R</given-names></name><etal/></person-group><article-title>Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer</article-title><source>Curr Med Res Opin</source><year>2018</year><volume>34</volume><issue>5</issue><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1080/03007995.2018.1439462</pub-id><pub-id pub-id-type="pmid">29424248</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, et al. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018;34(5):865&#8211;71.<pub-id pub-id-type="pmid">29424248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03007995.2018.1439462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Visser S, Huisbrink J, van 't Veer NE, van Toor JJ, van Boxem AJM, van Walree NC, et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. 2018;52(4).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00884-2018</pub-id><pub-id pub-id-type="pmid">30139775</pub-id></mixed-citation></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mita</surname><given-names>AC</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SD</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>A</given-names></name><name name-style="western"><surname>Hammond</surname><given-names>LA</given-names></name><name name-style="western"><surname>Patnaik</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>4</issue><fpage>552</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.00.9720</pub-id><pub-id pub-id-type="pmid">16391300</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552&#8211;62.<pub-id pub-id-type="pmid">16391300</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2004.00.9720</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Rouw</surname><given-names>N</given-names></name><name name-style="western"><surname>Piet</surname><given-names>B</given-names></name><name name-style="western"><surname>Derijks</surname><given-names>HJ</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>MM</given-names></name><name name-style="western"><surname>Ter Heine</surname><given-names>R</given-names></name></person-group><article-title>Mechanisms, management and prevention of pemetrexed-related toxicity</article-title><source>Drug Saf</source><year>2021</year><volume>44</volume><issue>12</issue><fpage>1271</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1007/s40264-021-01135-2</pub-id><pub-id pub-id-type="pmid">34741752</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">de Rouw N, Piet B, Derijks HJ, van den Heuvel MM, Ter Heine R. Mechanisms, management and prevention of pemetrexed-related toxicity. Drug Saf. 2021;44(12):1271&#8211;81.<pub-id pub-id-type="pmid">34741752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-021-01135-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cullen</surname><given-names>MH</given-names></name><name name-style="western"><surname>Zatloukal</surname><given-names>P</given-names></name><name name-style="western"><surname>S&#246;renson</surname><given-names>S</given-names></name><name name-style="western"><surname>Novello</surname><given-names>S</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Joy</surname><given-names>AA</given-names></name><etal/></person-group><article-title>A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>5</issue><fpage>939</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdm592</pub-id><pub-id pub-id-type="pmid">18283036</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Cullen MH, Zatloukal P, S&#246;renson S, Novello S, Fischer JR, Joy AA, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2008;19(5):939&#8211;45.<pub-id pub-id-type="pmid">18283036</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdm592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, et al. A randomized phase II study of 500 mg/m2 and 1,000 mg/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy. J Clin Oncol. 2007;25(18_suppl):7590.</mixed-citation></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanna</surname><given-names>N</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>FA</given-names></name><name name-style="western"><surname>Fossella</surname><given-names>FV</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>JR</given-names></name><name name-style="western"><surname>De Marinis</surname><given-names>F</given-names></name><name name-style="western"><surname>von Pawel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>9</issue><fpage>1589</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.08.163</pub-id><pub-id pub-id-type="pmid">15117980</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589&#8211;97.<pub-id pub-id-type="pmid">15117980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2004.08.163</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Rouw</surname><given-names>N</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>M</given-names></name><name name-style="western"><surname>Boosman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>MM</given-names></name><name name-style="western"><surname>Burger</surname><given-names>DM</given-names></name><name name-style="western"><surname>Lieverse</surname><given-names>JE</given-names></name><etal/></person-group><article-title>The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer</article-title><source>Clin Pharmacol Ther</source><year>2022</year><volume>111</volume><issue>5</issue><fpage>1103</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1002/cpt.2529</pub-id><pub-id pub-id-type="pmid">35048355</pub-id><pub-id pub-id-type="pmcid">PMC9304220</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">de Rouw N, de Boer M, Boosman RJ, van den Heuvel MM, Burger DM, Lieverse JE, et al. The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer. Clin Pharmacol Ther. 2022;111(5):1103&#8211;10.<pub-id pub-id-type="pmid">35048355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.2529</pub-id><pub-id pub-id-type="pmcid">PMC9304220</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><mixed-citation publication-type="other">de Rouw N, Beunders R, Hartmann O, Schulte J, Boosman RJ, Derijks HJ, et al. A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed. Cancer Chemother Pharmacol. 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-024-04717-w</pub-id><pub-id pub-id-type="pmcid">PMC11573856</pub-id><pub-id pub-id-type="pmid">39365467</pub-id></mixed-citation></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Rouw</surname><given-names>N</given-names></name><name name-style="western"><surname>Visser</surname><given-names>S</given-names></name><name name-style="western"><surname>Koolen</surname><given-names>SLW</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>J</given-names></name><name name-style="western"><surname>van den Heuvel</surname><given-names>MM</given-names></name><name name-style="western"><surname>Derijks</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions</article-title><source>Cancer Chemother Pharmacol</source><year>2020</year><volume>85</volume><issue>1</issue><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1007/s00280-019-04006-x</pub-id><pub-id pub-id-type="pmid">31853639</pub-id><pub-id pub-id-type="pmcid">PMC6994532</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">de Rouw N, Visser S, Koolen SLW, Aerts J, van den Heuvel MM, Derijks HJ, et al. A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Cancer Chemother Pharmacol. 2020;85(1):231&#8211;5.<pub-id pub-id-type="pmid">31853639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-019-04006-x</pub-id><pub-id pub-id-type="pmcid">PMC6994532</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name><name name-style="western"><surname>Lahens</surname><given-names>NF</given-names></name><name name-style="western"><surname>Ballance</surname><given-names>HI</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>ME</given-names></name><name name-style="western"><surname>Hogenesch</surname><given-names>JB</given-names></name></person-group><article-title>A circadian gene expression atlas in mammals: implications for biology and medicine</article-title><source>Proc Natl Acad Sci U S A</source><year>2014</year><volume>111</volume><issue>45</issue><fpage>16219</fpage><lpage>16224</lpage><pub-id pub-id-type="doi">10.1073/pnas.1408886111</pub-id><pub-id pub-id-type="pmid">25349387</pub-id><pub-id pub-id-type="pmcid">PMC4234565</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 2014;111(45):16219&#8211;24.<pub-id pub-id-type="pmid">25349387</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1408886111</pub-id><pub-id pub-id-type="pmcid">PMC4234565</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><mixed-citation publication-type="other">Sun L-Y, Xu Q-A, Xu X, Xian K-X, Zeng X-X, Li H-G, Zhang X-H. Efficacy and safety of time-of-day infusion of pemetrexed plus platinum and paclitaxel plus platinum for patients with advanced non-small cell lung cancer: a retrospective study. J Clin Oncol. 2024;42(16_suppl):e20557-e.</mixed-citation></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Pfeifer</surname><given-names>BA</given-names></name></person-group><article-title>Current and emerging options for taxol production</article-title><source>Adv Biochem Eng Biotechnol</source><year>2015</year><volume>148</volume><fpage>405</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">25528175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/10_2014_292</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Li Y, Zhang G, Pfeifer BA. Current and emerging options for taxol production. Adv Biochem Eng Biotechnol. 2015;148:405&#8211;25.<pub-id pub-id-type="pmid">25528175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/10_2014_292</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosca</surname><given-names>L</given-names></name><name name-style="western"><surname>Ilari</surname><given-names>A</given-names></name><name name-style="western"><surname>Fazi</surname><given-names>F</given-names></name><name name-style="western"><surname>Assaraf</surname><given-names>YG</given-names></name><name name-style="western"><surname>Colotti</surname><given-names>G</given-names></name></person-group><article-title>Taxanes in cancer treatment: activity, chemoresistance and its overcoming</article-title><source>Drug Resist Updat</source><year>2021</year><volume>54</volume><fpage>100742</fpage><pub-id pub-id-type="doi">10.1016/j.drup.2020.100742</pub-id><pub-id pub-id-type="pmid">33429249</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54: 100742.<pub-id pub-id-type="pmid">33429249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drup.2020.100742</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Rivory</surname><given-names>LP</given-names></name></person-group><article-title>Clinical pharmacokinetics of docetaxel</article-title><source>Clin Pharmacokinet</source><year>1999</year><volume>36</volume><issue>2</issue><fpage>99</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.2165/00003088-199936020-00002</pub-id><pub-id pub-id-type="pmid">10092957</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36(2):99&#8211;114.<pub-id pub-id-type="pmid">10092957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-199936020-00002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name><name name-style="western"><surname>van Tellingen</surname><given-names>O</given-names></name><name name-style="western"><surname>Nooijen</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name></person-group><article-title>Preclinical pharmacokinetics of paclitaxel and docetaxel</article-title><source>Anticancer Drugs</source><year>1998</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1097/00001813-199801000-00001</pub-id><pub-id pub-id-type="pmid">9491787</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs. 1998;9(1):1&#8211;17.<pub-id pub-id-type="pmid">9491787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00001813-199801000-00001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eisenhauer</surname><given-names>EA</given-names></name><name name-style="western"><surname>ten Bokkel Huinink</surname><given-names>WW</given-names></name><name name-style="western"><surname>Swenerton</surname><given-names>KD</given-names></name><name name-style="western"><surname>Gianni</surname><given-names>L</given-names></name><name name-style="western"><surname>Myles</surname><given-names>J</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>ME</given-names></name><etal/></person-group><article-title>European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><issue>12</issue><fpage>2654</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1200/JCO.1994.12.12.2654</pub-id><pub-id pub-id-type="pmid">7989941</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654&#8211;66.<pub-id pub-id-type="pmid">7989941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1994.12.12.2654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><mixed-citation publication-type="other">EMA. European Medicines Agency - TAXOTERE (INN-docetaxel) - Product information (EPAR). 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf</ext-link>. Accessed 05 Dec 2024.</mixed-citation></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muth</surname><given-names>M</given-names></name><name name-style="western"><surname>Ojara</surname><given-names>FW</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C</given-names></name><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name></person-group><article-title>Role of TDM-based dose adjustments for taxane anticancer drugs</article-title><source>Br J Clin Pharmacol</source><year>2021</year><volume>87</volume><issue>2</issue><fpage>306</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1111/bcp.14678</pub-id><pub-id pub-id-type="pmid">33247980</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Muth M, Ojara FW, Kloft C, Joerger M. Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol. 2021;87(2):306&#8211;16.<pub-id pub-id-type="pmid">33247980</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoneshima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Morita</surname><given-names>S</given-names></name><name name-style="western"><surname>Ando</surname><given-names>M</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>A</given-names></name><name name-style="western"><surname>Iwasawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC</article-title><source>J Thorac Oncol</source><year>2021</year><volume>16</volume><issue>9</issue><fpage>1523</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2021.03.027</pub-id><pub-id pub-id-type="pmid">33915251</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021;16(9):1523&#8211;32.<pub-id pub-id-type="pmid">33915251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jtho.2021.03.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Socinski</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bondarenko</surname><given-names>I</given-names></name><name name-style="western"><surname>Karaseva</surname><given-names>NA</given-names></name><name name-style="western"><surname>Makhson</surname><given-names>AM</given-names></name><name name-style="western"><surname>Vynnychenko</surname><given-names>I</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>I</given-names></name><etal/></person-group><article-title>Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>17</issue><fpage>2055</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.39.5848</pub-id><pub-id pub-id-type="pmid">22547591</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055&#8211;62.<pub-id pub-id-type="pmid">22547591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2011.39.5848</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serpico</surname><given-names>AF</given-names></name><name name-style="western"><surname>Visconti</surname><given-names>R</given-names></name><name name-style="western"><surname>Grieco</surname><given-names>D</given-names></name></person-group><article-title>Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment</article-title><source>Cell Death Dis</source><year>2020</year><volume>11</volume><issue>5</issue><fpage>361</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-2567-0</pub-id><pub-id pub-id-type="pmid">32398657</pub-id><pub-id pub-id-type="pmcid">PMC7217828</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Serpico AF, Visconti R, Grieco D. Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death Dis. 2020;11(5):361.<pub-id pub-id-type="pmid">32398657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-020-2567-0</pub-id><pub-id pub-id-type="pmcid">PMC7217828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kampan</surname><given-names>NC</given-names></name><name name-style="western"><surname>Madondo</surname><given-names>MT</given-names></name><name name-style="western"><surname>McNally</surname><given-names>OM</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>M</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M</given-names></name></person-group><article-title>Paclitaxel and its evolving role in the management of ovarian cancer</article-title><source>Biomed Res Int</source><year>2015</year><volume>2015</volume><fpage>413076</fpage><pub-id pub-id-type="doi">10.1155/2015/413076</pub-id><pub-id pub-id-type="pmid">26137480</pub-id><pub-id pub-id-type="pmcid">PMC4475536</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015: 413076.<pub-id pub-id-type="pmid">26137480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2015/413076</pub-id><pub-id pub-id-type="pmcid">PMC4475536</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muta</surname><given-names>M</given-names></name><name name-style="western"><surname>Yanagawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Sai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Saji</surname><given-names>S</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>E</given-names></name><name name-style="western"><surname>Aruga</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells</article-title><source>Oncology</source><year>2009</year><volume>77</volume><issue>3&#8211;4</issue><fpage>182</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1159/000236016</pub-id><pub-id pub-id-type="pmid">19729975</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T, et al. Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. Oncology. 2009;77(3&#8211;4):182&#8211;91.<pub-id pub-id-type="pmid">19729975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000236016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urien</surname><given-names>S</given-names></name><name name-style="western"><surname>Barr&#233;</surname><given-names>J</given-names></name><name name-style="western"><surname>Morin</surname><given-names>C</given-names></name><name name-style="western"><surname>Paccaly</surname><given-names>A</given-names></name><name name-style="western"><surname>Montay</surname><given-names>G</given-names></name><name name-style="western"><surname>Tillement</surname><given-names>JP</given-names></name></person-group><article-title>Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein</article-title><source>Invest New Drugs</source><year>1996</year><volume>14</volume><issue>2</issue><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1007/BF00210785</pub-id><pub-id pub-id-type="pmid">8913835</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Urien S, Barr&#233; J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs. 1996;14(2):147&#8211;51.<pub-id pub-id-type="pmid">8913835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00210785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>R</given-names></name><name name-style="western"><surname>Vivier</surname><given-names>N</given-names></name><name name-style="western"><surname>Vergniol</surname><given-names>JC</given-names></name><name name-style="western"><surname>De Phillips</surname><given-names>SL</given-names></name><name name-style="western"><surname>Montay</surname><given-names>G</given-names></name><name name-style="western"><surname>Sheiner</surname><given-names>LB</given-names></name></person-group><article-title>A population pharmacokinetic model for docetaxel (Taxotere): model building and validation</article-title><source>J Pharmacokinet Biopharm</source><year>1996</year><volume>24</volume><issue>2</issue><fpage>153</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/BF02353487</pub-id><pub-id pub-id-type="pmid">8875345</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24(2):153&#8211;72.<pub-id pub-id-type="pmid">8875345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02353487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudek</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name><name name-style="western"><surname>Garrett-Mayer</surname><given-names>ES</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>DK</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>AC</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name><name name-style="western"><surname>Baker</surname><given-names>SD</given-names></name></person-group><article-title>Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy</article-title><source>Eur J Cancer</source><year>2004</year><volume>40</volume><issue>8</issue><fpage>1170</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2003.12.026</pub-id><pub-id pub-id-type="pmid">15110880</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004;40(8):1170&#8211;8.<pub-id pub-id-type="pmid">15110880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2003.12.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>R</given-names></name><name name-style="western"><surname>Hille</surname><given-names>D</given-names></name><name name-style="western"><surname>Riva</surname><given-names>A</given-names></name><name name-style="western"><surname>Vivier</surname><given-names>N</given-names></name><name name-style="western"><surname>ten Bokkel Huinnink</surname><given-names>WW</given-names></name><name name-style="western"><surname>van Oosterom</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><issue>1</issue><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1200/JCO.1998.16.1.187</pub-id><pub-id pub-id-type="pmid">9440742</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187&#8211;96.<pub-id pub-id-type="pmid">9440742</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1998.16.1.187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombard</surname><given-names>A</given-names></name><name name-style="western"><surname>Mistry</surname><given-names>H</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>L</given-names></name><name name-style="western"><surname>Ogungbenro</surname><given-names>K</given-names></name></person-group><article-title>Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients</article-title><source>Br J Clin Pharmacol</source><year>2021</year><volume>87</volume><issue>4</issue><fpage>2053</fpage><lpage>2063</lpage><pub-id pub-id-type="doi">10.1111/bcp.14614</pub-id><pub-id pub-id-type="pmid">33075149</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Lombard A, Mistry H, Aarons L, Ogungbenro K. Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol. 2021;87(4):2053&#8211;63.<pub-id pub-id-type="pmid">33075149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14614</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallis</surname><given-names>AG</given-names></name><name name-style="western"><surname>Agelaki</surname><given-names>S</given-names></name><name name-style="western"><surname>Kakolyris</surname><given-names>S</given-names></name><name name-style="western"><surname>Kotsakis</surname><given-names>A</given-names></name><name name-style="western"><surname>Kalykaki</surname><given-names>A</given-names></name><name name-style="western"><surname>Vardakis</surname><given-names>N</given-names></name><etal/></person-group><article-title>Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy</article-title><source>Lung Cancer</source><year>2008</year><volume>62</volume><issue>3</issue><fpage>356</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2008.03.030</pub-id><pub-id pub-id-type="pmid">18501466</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer. 2008;62(3):356&#8211;63.<pub-id pub-id-type="pmid">18501466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lungcan.2008.03.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosch</surname><given-names>TM</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>AD</given-names></name><name name-style="western"><surname>Doodeman</surname><given-names>VD</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>R</given-names></name><name name-style="western"><surname>Witteveen</surname><given-names>E</given-names></name><name name-style="western"><surname>Smit</surname><given-names>WM</given-names></name><etal/></person-group><article-title>Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><issue>19</issue><fpage>5786</fpage><lpage>5793</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2649</pub-id><pub-id pub-id-type="pmid">17020985</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12(19):5786&#8211;93.<pub-id pub-id-type="pmid">17020985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-05-2649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>A</given-names></name><name name-style="western"><surname>Jullien</surname><given-names>V</given-names></name><name name-style="western"><surname>Alexandre</surname><given-names>J</given-names></name><name name-style="western"><surname>Rey</surname><given-names>E</given-names></name><name name-style="western"><surname>Rabillon</surname><given-names>F</given-names></name><name name-style="western"><surname>Girre</surname><given-names>V</given-names></name><etal/></person-group><article-title>Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>79</volume><issue>6</issue><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2006.02.003</pub-id><pub-id pub-id-type="pmid">16765145</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006;79(6):570&#8211;80.<pub-id pub-id-type="pmid">16765145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2006.02.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirth</surname><given-names>J</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name><name name-style="western"><surname>Strawderman</surname><given-names>M</given-names></name><name name-style="western"><surname>Schott</surname><given-names>A</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R</given-names></name><name name-style="western"><surname>Baker</surname><given-names>LH</given-names></name></person-group><article-title>The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><issue>4</issue><fpage>1255</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">10778948</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual&#8217;s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6(4):1255&#8211;8.<pub-id pub-id-type="pmid">10778948</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilli</surname><given-names>J</given-names></name><name name-style="western"><surname>Sailas</surname><given-names>L</given-names></name><name name-style="western"><surname>Jyrkki&#246;</surname><given-names>S</given-names></name><name name-style="western"><surname>Pyrh&#246;nen</surname><given-names>S</given-names></name><name name-style="western"><surname>Laine</surname><given-names>K</given-names></name></person-group><article-title><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01110291">NCT01110291</ext-link>: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2011</year><volume>67</volume><issue>6</issue><fpage>1353</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1007/s00280-010-1426-6</pub-id><pub-id pub-id-type="pmid">20798939</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Hilli J, Sailas L, Jyrkki&#246; S, Pyrh&#246;nen S, Laine K. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01110291">NCT01110291</ext-link>: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol. 2011;67(6):1353&#8211;62.<pub-id pub-id-type="pmid">20798939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-010-1426-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamboni</surname><given-names>WC</given-names></name><name name-style="western"><surname>Combest</surname><given-names>AJ</given-names></name><name name-style="western"><surname>DeLoia</surname><given-names>JA</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>RP</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>AS</given-names></name><name name-style="western"><surname>Zamboni</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2011</year><volume>68</volume><issue>5</issue><fpage>1255</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1007/s00280-011-1609-9</pub-id><pub-id pub-id-type="pmid">21437702</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol. 2011;68(5):1255&#8211;62.<pub-id pub-id-type="pmid">21437702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-011-1609-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>N</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Kamiya</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sekine</surname><given-names>I</given-names></name><name name-style="western"><surname>Kunitoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>N</given-names></name></person-group><article-title>Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><issue>11</issue><fpage>2301</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1200/JCO.2000.18.11.2301</pub-id><pub-id pub-id-type="pmid">10829051</pub-id></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol. 2000;18(11):2301&#8211;8.<pub-id pub-id-type="pmid">10829051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2000.18.11.2301</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>N</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>H</given-names></name><name name-style="western"><surname>Shimoyama</surname><given-names>T</given-names></name><name name-style="western"><surname>Nokihara</surname><given-names>H</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>6</issue><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.11.036</pub-id><pub-id pub-id-type="pmid">15657405</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005;23(6):1061&#8211;9.<pub-id pub-id-type="pmid">15657405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.11.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirano</surname><given-names>R</given-names></name><name name-style="western"><surname>Yokokawa</surname><given-names>A</given-names></name><name name-style="western"><surname>Furihata</surname><given-names>T</given-names></name><name name-style="western"><surname>Shibasaki</surname><given-names>H</given-names></name></person-group><article-title>Plasma 6&#946;-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method</article-title><source>Br J Clin Pharmacol</source><year>2024</year><volume>90</volume><issue>4</issue><fpage>1016</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1111/bcp.15987</pub-id><pub-id pub-id-type="pmid">38102865</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Hirano R, Yokokawa A, Furihata T, Shibasaki H. Plasma 6&#946;-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method. Br J Clin Pharmacol. 2024;90(4):1016&#8211;26.<pub-id pub-id-type="pmid">38102865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.15987</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><mixed-citation publication-type="other">Heerma van Voss MR, Notohardjo J, van Dodewaard-de Jong J, Bloemendal HJ, Heine RT. A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer Chemother Pharmacol. 2024.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-024-04684-2</pub-id><pub-id pub-id-type="pmcid">PMC11420247</pub-id><pub-id pub-id-type="pmid">38951305</pub-id></mixed-citation></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshino</surname><given-names>E</given-names></name><name name-style="western"><surname>Kawara</surname><given-names>K</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2015</year><volume>76</volume><issue>4</issue><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1007/s00280-015-2844-2</pub-id><pub-id pub-id-type="pmid">26297058</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Fujita K, Yoshino E, Kawara K, Maeda K, Kusuhara H, Sugiyama Y, et al. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Cancer Chemother Pharmacol. 2015;76(4):793&#8211;801.<pub-id pub-id-type="pmid">26297058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-015-2844-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bria</surname><given-names>E</given-names></name><name name-style="western"><surname>Cuppone</surname><given-names>F</given-names></name><name name-style="western"><surname>Ciccarese</surname><given-names>M</given-names></name><name name-style="western"><surname>Nistic&#242;</surname><given-names>C</given-names></name><name name-style="western"><surname>Facciolo</surname><given-names>F</given-names></name><name name-style="western"><surname>Milella</surname><given-names>M</given-names></name><etal/></person-group><article-title>Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials</article-title><source>Cancer Treat Rev</source><year>2006</year><volume>32</volume><issue>8</issue><fpage>583</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2006.07.003</pub-id><pub-id pub-id-type="pmid">16919884</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Bria E, Cuppone F, Ciccarese M, Nistic&#242; C, Facciolo F, Milella M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006;32(8):583&#8211;7.<pub-id pub-id-type="pmid">16919884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2006.07.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engels</surname><given-names>FK</given-names></name><name name-style="western"><surname>Loos</surname><given-names>WJ</given-names></name><name name-style="western"><surname>van der Bol</surname><given-names>JM</given-names></name><name name-style="western"><surname>de Bruijn</surname><given-names>P</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RH</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name><name name-style="western"><surname>Mathot</surname><given-names>RA</given-names></name></person-group><article-title>Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><issue>2</issue><fpage>353</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1636</pub-id><pub-id pub-id-type="pmid">21224369</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res. 2011;17(2):353&#8211;62.<pub-id pub-id-type="pmid">21224369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-10-1636</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries Schultink</surname><given-names>AHM</given-names></name><name name-style="western"><surname>Crombag</surname><given-names>MBS</given-names></name><name name-style="western"><surname>van Werkhoven</surname><given-names>E</given-names></name><name name-style="western"><surname>Otten</surname><given-names>HM</given-names></name><name name-style="western"><surname>Bergman</surname><given-names>AM</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JHM</given-names></name><etal/></person-group><article-title>Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: a meta-analysis and evaluation of a clinical cohort</article-title><source>Cancer Med</source><year>2019</year><volume>8</volume><issue>4</issue><fpage>1406</fpage><lpage>1415</lpage><pub-id pub-id-type="doi">10.1002/cam4.2003</pub-id><pub-id pub-id-type="pmid">30802002</pub-id><pub-id pub-id-type="pmcid">PMC6488109</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, et al. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: a meta-analysis and evaluation of a clinical cohort. Cancer Med. 2019;8(4):1406&#8211;15.<pub-id pub-id-type="pmid">30802002</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cam4.2003</pub-id><pub-id pub-id-type="pmcid">PMC6488109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallin</surname><given-names>JE</given-names></name><name name-style="western"><surname>Friberg</surname><given-names>LE</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>MO</given-names></name></person-group><article-title>Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2010</year><volume>106</volume><issue>3</issue><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2009.00520.x</pub-id><pub-id pub-id-type="pmid">20050841</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Wallin JE, Friberg LE, Karlsson MO. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol. 2010;106(3):234&#8211;42.<pub-id pub-id-type="pmid">20050841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2009.00520.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stage</surname><given-names>TB</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>TK</given-names></name><name name-style="western"><surname>Kroetz</surname><given-names>DL</given-names></name></person-group><article-title>Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review</article-title><source>Clin Pharmacokinet</source><year>2018</year><volume>57</volume><issue>1</issue><fpage>7</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/s40262-017-0563-z</pub-id><pub-id pub-id-type="pmid">28612269</pub-id><pub-id pub-id-type="pmcid">PMC8572663</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Stage TB, Bergmann TK, Kroetz DL. Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. Clin Pharmacokinet. 2018;57(1):7&#8211;19.<pub-id pub-id-type="pmid">28612269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-017-0563-z</pub-id><pub-id pub-id-type="pmcid">PMC8572663</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hertz</surname><given-names>DL</given-names></name><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Bang</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Mathijssen</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Paclitaxel therapeutic drug monitoring&#8212;international association of therapeutic drug monitoring and clinical toxicology recommendations</article-title><source>Eur J Cancer</source><year>2024</year><volume>202</volume><fpage>114024</fpage><pub-id pub-id-type="doi">10.1016/j.ejca.2024.114024</pub-id><pub-id pub-id-type="pmid">38513383</pub-id><pub-id pub-id-type="pmcid">PMC11053297</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, et al. Paclitaxel therapeutic drug monitoring&#8212;international association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024;202: 114024.<pub-id pub-id-type="pmid">38513383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2024.114024</pub-id><pub-id pub-id-type="pmcid">PMC11053297</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><mixed-citation publication-type="other">Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15(1):317&#8211;29.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1997.15.1.317</pub-id><pub-id pub-id-type="pmid">8996159</pub-id></mixed-citation></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>AD</given-names></name><name name-style="western"><surname>Huizing</surname><given-names>MT</given-names></name><name name-style="western"><surname>Willemse</surname><given-names>PH</given-names></name><name name-style="western"><surname>de Graeff</surname><given-names>A</given-names></name><name name-style="western"><surname>Rosing</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study</article-title><source>Br J Clin Pharmacol</source><year>2007</year><volume>64</volume><issue>5</issue><fpage>622</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2007.02956.x</pub-id><pub-id pub-id-type="pmid">17935602</pub-id><pub-id pub-id-type="pmcid">PMC2203269</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2007;64(5):622&#8211;33.<pub-id pub-id-type="pmid">17935602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2007.02956.x</pub-id><pub-id pub-id-type="pmcid">PMC2203269</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biakhov</surname><given-names>MY</given-names></name><name name-style="western"><surname>Kononova</surname><given-names>GV</given-names></name><name name-style="western"><surname>Iglesias</surname><given-names>J</given-names></name><name name-style="western"><surname>Desai</surname><given-names>N</given-names></name><name name-style="western"><surname>Bhar</surname><given-names>P</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>AN</given-names></name><name name-style="western"><surname>Loibl</surname><given-names>S</given-names></name></person-group><article-title>nab-Paclitaxel in patients with advanced solid tumours and hepatic dysfunction: a pilot study</article-title><source>Expert Opin Drug Saf</source><year>2010</year><volume>9</volume><issue>4</issue><fpage>515</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1517/14740338.2010.487063</pub-id><pub-id pub-id-type="pmid">20500029</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Biakhov MY, Kononova GV, Iglesias J, Desai N, Bhar P, Schmid AN, Loibl S. nab-Paclitaxel in patients with advanced solid tumours and hepatic dysfunction: a pilot study. Expert Opin Drug Saf. 2010;9(4):515&#8211;23.<pub-id pub-id-type="pmid">20500029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14740338.2010.487063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Palmisano</surname><given-names>M</given-names></name><name name-style="western"><surname>Chopra</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumours: disposition kinetics and pharmacology distinct from solvent-based paclitaxel</article-title><source>J Clin Pharmacol</source><year>2014</year><volume>54</volume><issue>10</issue><fpage>1097</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1002/jcph.304</pub-id><pub-id pub-id-type="pmid">24719309</pub-id><pub-id pub-id-type="pmcid">PMC4302229</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumours: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014;54(10):1097&#8211;107.<pub-id pub-id-type="pmid">24719309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.304</pub-id><pub-id pub-id-type="pmcid">PMC4302229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>AD</given-names></name><name name-style="western"><surname>van den Bongard</surname><given-names>DH</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JH</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name></person-group><article-title>Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumours</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><issue>7 Pt 1</issue><fpage>2150</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2069</pub-id><pub-id pub-id-type="pmid">16609028</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumours. Clin Cancer Res. 2006;12(7 Pt 1):2150&#8211;7.<pub-id pub-id-type="pmid">16609028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-05-2069</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name></person-group><article-title>Metabolism of the taxanes including nab-paclitaxel</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2015</year><volume>11</volume><issue>5</issue><fpage>691</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1517/17425255.2015.983074</pub-id><pub-id pub-id-type="pmid">25394848</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Joerger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol. 2015;11(5):691&#8211;702.<pub-id pub-id-type="pmid">25394848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2015.983074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis</article-title><source>Crit Rev Oncol Hematol</source><year>2019</year><volume>139</volume><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.04.021</pub-id><pub-id pub-id-type="pmid">31112878</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, et al. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;139:16&#8211;23.<pub-id pub-id-type="pmid">31112878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2019.04.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergmann</surname><given-names>TK</given-names></name><name name-style="western"><surname>Brasch-Andersen</surname><given-names>C</given-names></name><name name-style="western"><surname>Gr&#233;en</surname><given-names>H</given-names></name><name name-style="western"><surname>Mirza</surname><given-names>M</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>RS</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer</article-title><source>Pharmacogenom J</source><year>2011</year><volume>11</volume><issue>2</issue><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/tpj.2010.19</pub-id><pub-id pub-id-type="pmid">20368717</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Bergmann TK, Brasch-Andersen C, Gr&#233;en H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenom J. 2011;11(2):113&#8211;20.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/tpj.2010.19</pub-id><pub-id pub-id-type="pmid">20368717</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hertz</surname><given-names>DL</given-names></name><name name-style="western"><surname>Motsinger-Reif</surname><given-names>AA</given-names></name><name name-style="western"><surname>Drobish</surname><given-names>A</given-names></name><name name-style="western"><surname>Winham</surname><given-names>SJ</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>HL</given-names></name><name name-style="western"><surname>Carey</surname><given-names>LA</given-names></name><name name-style="western"><surname>Dees</surname><given-names>EC</given-names></name></person-group><article-title>CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel</article-title><source>Breast Cancer Res Treat</source><year>2012</year><volume>134</volume><issue>1</issue><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1007/s10549-012-2054-0</pub-id><pub-id pub-id-type="pmid">22527101</pub-id><pub-id pub-id-type="pmcid">PMC3727245</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012;134(1):401&#8211;10.<pub-id pub-id-type="pmid">22527101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10549-012-2054-0</pub-id><pub-id pub-id-type="pmcid">PMC3727245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sissung</surname><given-names>TM</given-names></name><name name-style="western"><surname>Mross</surname><given-names>K</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>SM</given-names></name><name name-style="western"><surname>Behringer</surname><given-names>D</given-names></name><name name-style="western"><surname>Figg</surname><given-names>WD</given-names></name><name name-style="western"><surname>Sparreboom</surname><given-names>A</given-names></name><name name-style="western"><surname>Mielke</surname><given-names>S</given-names></name></person-group><article-title>Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia</article-title><source>Eur J Cancer</source><year>2006</year><volume>42</volume><issue>17</issue><fpage>2893</fpage><lpage>2896</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2006.06.017</pub-id><pub-id pub-id-type="pmid">16950614</pub-id><pub-id pub-id-type="pmcid">PMC1647318</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006;42(17):2893&#8211;6.<pub-id pub-id-type="pmid">16950614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2006.06.017</pub-id><pub-id pub-id-type="pmcid">PMC1647318</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>H</given-names></name><name name-style="western"><surname>Rha</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jeung</surname><given-names>HC</given-names></name><name name-style="western"><surname>Im</surname><given-names>CK</given-names></name><name name-style="western"><surname>Noh</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chung</surname><given-names>HC</given-names></name></person-group><article-title>Association of the ABCB1 3435C&gt;T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy</article-title><source>Oncol Rep</source><year>2010</year><volume>23</volume><issue>1</issue><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">19956892</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Chang H, Rha SY, Jeung HC, Im CK, Noh SH, Kim JJ, Chung HC. Association of the ABCB1 3435C&gt;T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep. 2010;23(1):271&#8211;8.<pub-id pub-id-type="pmid">19956892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>TC</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>TC</given-names></name></person-group><article-title>Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumours: a meta-analysis</article-title><source>Cancer Treat Rev</source><year>2012</year><volume>38</volume><issue>6</issue><fpage>613</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2011.10.008</pub-id><pub-id pub-id-type="pmid">22155063</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumours: a meta-analysis. Cancer Treat Rev. 2012;38(6):613&#8211;7.<pub-id pub-id-type="pmid">22155063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctrv.2011.10.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Socinski</surname><given-names>MA</given-names></name><name name-style="western"><surname>Manikhas</surname><given-names>GM</given-names></name><name name-style="western"><surname>Stroyakovsky</surname><given-names>DL</given-names></name><name name-style="western"><surname>Makhson</surname><given-names>AN</given-names></name><name name-style="western"><surname>Cheporov</surname><given-names>SV</given-names></name><name name-style="western"><surname>Orlov</surname><given-names>SV</given-names></name><etal/></person-group><article-title>A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer</article-title><source>J Thorac Oncol</source><year>2010</year><volume>5</volume><issue>6</issue><fpage>852</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3181d5e39e</pub-id><pub-id pub-id-type="pmid">20521351</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(6):852&#8211;61.<pub-id pub-id-type="pmid">20521351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/jto.0b013e3181d5e39e</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gradishar</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Krasnojon</surname><given-names>D</given-names></name><name name-style="western"><surname>Cheporov</surname><given-names>S</given-names></name><name name-style="western"><surname>Makhson</surname><given-names>AN</given-names></name><name name-style="western"><surname>Manikhas</surname><given-names>GM</given-names></name><name name-style="western"><surname>Clawson</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhar</surname><given-names>P</given-names></name></person-group><article-title>Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>22</issue><fpage>3611</fpage><lpage>3619</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.5397</pub-id><pub-id pub-id-type="pmid">19470941</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611&#8211;9.<pub-id pub-id-type="pmid">19470941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2008.18.5397</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kan</surname><given-names>M</given-names></name><name name-style="western"><surname>Imaoka</surname><given-names>H</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study</article-title><source>Cancer Chemother Pharmacol</source><year>2020</year><volume>86</volume><issue>2</issue><fpage>203</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1007/s00280-020-04110-3</pub-id><pub-id pub-id-type="pmid">32632515</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Kan M, Imaoka H, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol. 2020;86(2):203&#8211;10.<pub-id pub-id-type="pmid">32632515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-020-04110-3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheithauer</surname><given-names>W</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>RK</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M</given-names></name><name name-style="western"><surname>Macarulla</surname><given-names>T</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>D</given-names></name><name name-style="western"><surname>Hammel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial</article-title><source>J Gastrointest Oncol.</source><year>2016</year><volume>7</volume><issue>3</issue><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.21037/jgo.2016.01.03</pub-id><pub-id pub-id-type="pmid">27284481</pub-id><pub-id pub-id-type="pmcid">PMC4880765</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7(3):469&#8211;78.<pub-id pub-id-type="pmid">27284481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/jgo.2016.01.03</pub-id><pub-id pub-id-type="pmcid">PMC4880765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joerger</surname><given-names>M</given-names></name><name name-style="western"><surname>Kraff</surname><given-names>S</given-names></name><name name-style="western"><surname>Jaehde</surname><given-names>U</given-names></name><name name-style="western"><surname>Hilger</surname><given-names>RA</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>JB</given-names></name><name name-style="western"><surname>Cline</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM)</article-title><source>Ther Drug Monit</source><year>2017</year><volume>39</volume><issue>6</issue><fpage>617</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000446</pub-id><pub-id pub-id-type="pmid">28937535</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, et al. Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM). Ther Drug Monit. 2017;39(6):617&#8211;24.<pub-id pub-id-type="pmid">28937535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mini</surname><given-names>E</given-names></name><name name-style="western"><surname>Nobili</surname><given-names>S</given-names></name><name name-style="western"><surname>Caciagli</surname><given-names>B</given-names></name><name name-style="western"><surname>Landini</surname><given-names>I</given-names></name><name name-style="western"><surname>Mazzei</surname><given-names>T</given-names></name></person-group><article-title>Cellular pharmacology of gemcitabine</article-title><source>Ann Oncol</source><year>2006</year><volume>17</volume><issue>Suppl 5</issue><fpage>v7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdj941</pub-id><pub-id pub-id-type="pmid">16807468</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7-12.<pub-id pub-id-type="pmid">16807468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdj941</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccolini</surname><given-names>J</given-names></name><name name-style="western"><surname>Serdjebi</surname><given-names>C</given-names></name><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Giovannetti</surname><given-names>E</given-names></name></person-group><article-title>Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective</article-title><source>Cancer Chemother Pharmacol</source><year>2016</year><volume>78</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s00280-016-3003-0</pub-id><pub-id pub-id-type="pmid">27007129</pub-id><pub-id pub-id-type="pmcid">PMC4921117</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78(1):1&#8211;12.<pub-id pub-id-type="pmid">27007129</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-016-3003-0</pub-id><pub-id pub-id-type="pmcid">PMC4921117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Clavel</surname><given-names>M</given-names></name><name name-style="western"><surname>Noordhuis</surname><given-names>P</given-names></name><name name-style="western"><surname>Geyssen</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Laan</surname><given-names>AC</given-names></name><name name-style="western"><surname>Guastalla</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule</article-title><source>J Chemother</source><year>2007</year><volume>19</volume><issue>2</issue><fpage>212</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1179/joc.2007.19.2.212</pub-id><pub-id pub-id-type="pmid">17434832</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla J, et al. Clinical phase I and pharmacology study of gemcitabine (2&#8217;, 2&#8217;-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother. 2007;19(2):212&#8211;21.<pub-id pub-id-type="pmid">17434832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1179/joc.2007.19.2.212</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinemann</surname><given-names>V</given-names></name><name name-style="western"><surname>Xu</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Chubb</surname><given-names>S</given-names></name><name name-style="western"><surname>Sen</surname><given-names>A</given-names></name><name name-style="western"><surname>Hertel</surname><given-names>LW</given-names></name><name name-style="western"><surname>Grindey</surname><given-names>GB</given-names></name><name name-style="western"><surname>Plunkett</surname><given-names>W</given-names></name></person-group><article-title>Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><issue>3</issue><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">1732039</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Cellular elimination of 2&#8217;,2&#8217;-difluorodeoxycytidine 5&#8217;-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52(3):533&#8211;9.<pub-id pub-id-type="pmid">1732039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grunewald</surname><given-names>R</given-names></name><name name-style="western"><surname>Abbruzzese</surname><given-names>JL</given-names></name><name name-style="western"><surname>Tarassoff</surname><given-names>P</given-names></name><name name-style="western"><surname>Plunkett</surname><given-names>W</given-names></name></person-group><article-title>Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine</article-title><source>Cancer Chemother Pharmacol</source><year>1991</year><volume>27</volume><issue>4</issue><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/BF00685109</pub-id><pub-id pub-id-type="pmid">1998982</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2&#8217;,2&#8217;-difluorodeoxycytidine 5&#8217;-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27(4):258&#8211;62.<pub-id pub-id-type="pmid">1998982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF00685109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veltkamp</surname><given-names>SA</given-names></name><name name-style="western"><surname>Pluim</surname><given-names>D</given-names></name><name name-style="western"><surname>van Eijndhoven</surname><given-names>MA</given-names></name><name name-style="western"><surname>Bolijn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ong</surname><given-names>FH</given-names></name><name name-style="western"><surname>Govindarajan</surname><given-names>R</given-names></name><etal/></person-group><article-title>New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine</article-title><source>Mol Cancer Ther</source><year>2008</year><volume>7</volume><issue>8</issue><fpage>2415</fpage><lpage>2425</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0137</pub-id><pub-id pub-id-type="pmid">18723487</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2&#8217;,2&#8217;-difluorodeoxyuridine. Mol Cancer Ther. 2008;7(8):2415&#8211;25.<pub-id pub-id-type="pmid">18723487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1535-7163.MCT-08-0137</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sugiyama</surname><given-names>E</given-names></name><name name-style="western"><surname>Kaniwa</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>R</given-names></name><name name-style="western"><surname>Saito</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>H</given-names></name><etal/></person-group><article-title>Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms</article-title><source>Clin Pharmacokinet</source><year>2010</year><volume>49</volume><issue>8</issue><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.2165/11532970-000000000-00000</pub-id><pub-id pub-id-type="pmid">20608756</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet. 2010;49(8):549&#8211;58.<pub-id pub-id-type="pmid">20608756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11532970-000000000-00000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boosman</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Crombag</surname><given-names>MBS</given-names></name><name name-style="western"><surname>van Erp</surname><given-names>NP</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Steeghs</surname><given-names>N</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>ADR</given-names></name></person-group><article-title>Is age just a number? A population pharmacokinetic study of gemcitabine</article-title><source>Cancer Chemother Pharmacol</source><year>2022</year><volume>89</volume><issue>5</issue><fpage>697</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1007/s00280-022-04431-5</pub-id><pub-id pub-id-type="pmid">35426526</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Boosman RJ, Crombag MBS, van Erp NP, Beijnen JH, Steeghs N, Huitema ADR. Is age just a number? A population pharmacokinetic study of gemcitabine. Cancer Chemother Pharmacol. 2022;89(5):697&#8211;705.<pub-id pub-id-type="pmid">35426526</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-022-04431-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerqueira</surname><given-names>NM</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>PA</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>MJ</given-names></name></person-group><article-title>Understanding ribonucleotide reductase inactivation by gemcitabine</article-title><source>Chemistry</source><year>2007</year><volume>13</volume><issue>30</issue><fpage>8507</fpage><lpage>8515</lpage><pub-id pub-id-type="doi">10.1002/chem.200700260</pub-id><pub-id pub-id-type="pmid">17636467</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry. 2007;13(30):8507&#8211;15.<pub-id pub-id-type="pmid">17636467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chem.200700260</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>MT</given-names></name><name name-style="western"><surname>Ding</surname><given-names>XX</given-names></name><name name-style="western"><surname>Hu</surname><given-names>JW</given-names></name><name name-style="western"><surname>Tian</surname><given-names>HY</given-names></name><name name-style="western"><surname>Yin</surname><given-names>R</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials</article-title><source>Cancer Chemother Pharmacol</source><year>2012</year><volume>70</volume><issue>6</issue><fpage>861</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1007/s00280-012-1974-z</pub-id><pub-id pub-id-type="pmid">23053260</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Qiu MT, Ding XX, Hu JW, Tian HY, Yin R, Xu L. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. Cancer Chemother Pharmacol. 2012;70(6):861&#8211;73.<pub-id pub-id-type="pmid">23053260</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-012-1974-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>GW</given-names></name><name name-style="western"><surname>Kang</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HG</given-names></name><name name-style="western"><surname>Kang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer</article-title><source>Cancer Chemother Pharmacol</source><year>2009</year><volume>64</volume><issue>2</issue><fpage>385</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s00280-008-0885-5</pub-id><pub-id pub-id-type="pmid">19104817</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Lee GW, Kang MH, Kim HG, Kang JH, Kim SH, Cho YJ, et al. Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer. Cancer Chemother Pharmacol. 2009;64(2):385&#8211;90.<pub-id pub-id-type="pmid">19104817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-008-0885-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locher</surname><given-names>C</given-names></name><name name-style="western"><surname>Fabre-Guillevin</surname><given-names>E</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Auroux</surname><given-names>J</given-names></name><name name-style="western"><surname>Delchier</surname><given-names>JC</given-names></name><name name-style="western"><surname>Piedbois</surname><given-names>P</given-names></name><name name-style="western"><surname>Zelek</surname><given-names>L</given-names></name></person-group><article-title>Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study</article-title><source>Crit Rev Oncol Hematol</source><year>2008</year><volume>68</volume><issue>2</issue><fpage>178</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2008.06.010</pub-id><pub-id pub-id-type="pmid">18672379</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Locher C, Fabre-Guillevin E, Brunetti F, Auroux J, Delchier JC, Piedbois P, Zelek L. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol. 2008;68(2):178&#8211;82.<pub-id pub-id-type="pmid">18672379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2008.06.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patil</surname><given-names>V</given-names></name><name name-style="western"><surname>Noronha</surname><given-names>V</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>A</given-names></name><name name-style="western"><surname>Chougule</surname><given-names>A</given-names></name><name name-style="western"><surname>Kannan</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhattacharjee</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer</article-title><source>EClinicalMedicine.</source><year>2019</year><volume>9</volume><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2019.03.011</pub-id><pub-id pub-id-type="pmid">31143878</pub-id><pub-id pub-id-type="pmcid">PMC6510888</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, et al. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019;9:19&#8211;25.<pub-id pub-id-type="pmid">31143878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2019.03.011</pub-id><pub-id pub-id-type="pmcid">PMC6510888</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>J</given-names></name><name name-style="western"><surname>Altaf</surname><given-names>K</given-names></name><name name-style="western"><surname>Ke</surname><given-names>N</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tan</surname><given-names>C</given-names></name><etal/></person-group><article-title>dCK expression and gene polymorphism with gemcitabine chemosensitivity in patients with pancreatic ductal adenocarcinoma: a strobe-compliant observational study</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><issue>10</issue><fpage>e2936</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000002936</pub-id><pub-id pub-id-type="pmid">26962792</pub-id><pub-id pub-id-type="pmcid">PMC4998873</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Xiong J, Altaf K, Ke N, Wang Y, Tang J, Tan C, et al. dCK expression and gene polymorphism with gemcitabine chemosensitivity in patients with pancreatic ductal adenocarcinoma: a strobe-compliant observational study. Medicine (Baltimore). 2016;95(10): e2936.<pub-id pub-id-type="pmid">26962792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000002936</pub-id><pub-id pub-id-type="pmcid">PMC4998873</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nordh</surname><given-names>S</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>D</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>R</given-names></name></person-group><article-title>hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><issue>26</issue><fpage>8482</fpage><lpage>8490</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i26.8482</pub-id><pub-id pub-id-type="pmid">25024604</pub-id><pub-id pub-id-type="pmcid">PMC4093699</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20(26):8482&#8211;90.<pub-id pub-id-type="pmid">25024604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v20.i26.8482</pub-id><pub-id pub-id-type="pmcid">PMC4093699</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vos</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>D</given-names></name><name name-style="western"><surname>Lui</surname><given-names>A</given-names></name><name name-style="western"><surname>Abdelaziz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Spratlin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Mackey</surname><given-names>JR</given-names></name></person-group><article-title>Predictive and prognostic properties of human equilibrative nucleoside transporter 1 expression in gemcitabine-treated pancreatobiliary cancer: a meta-analysis</article-title><source>JCO Precis Oncol</source><year>2019</year><volume>3</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1200/PO.18.00240</pub-id><pub-id pub-id-type="pmid">35100740</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Vos LJ, Yusuf D, Lui A, Abdelaziz Z, Ghosh S, Spratlin JL, Mackey JR. Predictive and prognostic properties of human equilibrative nucleoside transporter 1 expression in gemcitabine-treated pancreatobiliary cancer: a meta-analysis. JCO Precis Oncol. 2019;3:1&#8211;22.<pub-id pub-id-type="pmid">35100740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/PO.18.00240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozo</surname><given-names>D</given-names></name><name name-style="western"><surname>Ross</surname><given-names>MW</given-names></name><name name-style="western"><surname>Jarrah</surname><given-names>J</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>M</given-names></name><name name-style="western"><surname>Harney</surname><given-names>RL</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring</article-title><source>Ther Drug Monit</source><year>2017</year><volume>39</volume><issue>3</issue><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000402</pub-id><pub-id pub-id-type="pmid">28490046</pub-id><pub-id pub-id-type="pmcid">PMC5460533</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Kozo D, Ross MW, Jarrah J, Barrett M, Harney RL, Courtney JB, et al. Rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring. Ther Drug Monit. 2017;39(3):235&#8211;42.<pub-id pub-id-type="pmid">28490046</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FTD.0000000000000402</pub-id><pub-id pub-id-type="pmcid">PMC5460533</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fogli</surname><given-names>S</given-names></name><name name-style="western"><surname>Danesi</surname><given-names>R</given-names></name><name name-style="western"><surname>De Braud</surname><given-names>F</given-names></name><name name-style="western"><surname>De Pas</surname><given-names>T</given-names></name><name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></name><name name-style="western"><surname>Giovannetti</surname><given-names>G</given-names></name><name name-style="western"><surname>Del Tacca</surname><given-names>M</given-names></name></person-group><article-title>Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><issue>11</issue><fpage>1553</fpage><lpage>1559</lpage><pub-id pub-id-type="doi">10.1023/A:1013133415945</pub-id><pub-id pub-id-type="pmid">11822754</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti G, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol. 2001;12(11):1553&#8211;9.<pub-id pub-id-type="pmid">11822754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1013133415945</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capasso</surname><given-names>A</given-names></name></person-group><article-title>Vinorelbine in cancer therapy</article-title><source>Curr Drug Targets</source><year>2012</year><volume>13</volume><issue>8</issue><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.2174/138945012802009017</pub-id><pub-id pub-id-type="pmid">22594474</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Capasso A. Vinorelbine in cancer therapy. Curr Drug Targets. 2012;13(8):1065&#8211;71.<pub-id pub-id-type="pmid">22594474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/138945012802009017</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wargin</surname><given-names>WA</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>VS</given-names></name></person-group><article-title>The clinical pharmacokinetics of vinorelbine (Navelbine)</article-title><source>Semin Oncol</source><year>1994</year><volume>21</volume><issue>5 Suppl 10</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">7973765</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol. 1994;21(5 Suppl 10):21&#8211;7.<pub-id pub-id-type="pmid">7973765</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Balleine</surname><given-names>RL</given-names></name><name name-style="western"><surname>Blair</surname><given-names>EY</given-names></name><name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ackland</surname><given-names>SP</given-names></name><name name-style="western"><surname>Garg</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>16</issue><fpage>2448</fpage><lpage>2455</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.02.1295</pub-id><pub-id pub-id-type="pmid">16651648</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol. 2006;24(16):2448&#8211;55.<pub-id pub-id-type="pmid">16651648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2005.02.1295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piccirillo</surname><given-names>MC</given-names></name><name name-style="western"><surname>Daniele</surname><given-names>G</given-names></name><name name-style="western"><surname>Di Maio</surname><given-names>M</given-names></name><name name-style="western"><surname>Bryce</surname><given-names>J</given-names></name><name name-style="western"><surname>De Feo</surname><given-names>G</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>A</given-names></name><etal/></person-group><article-title>Vinorelbine for non-small cell lung cancer</article-title><source>Expert Opin Drug Saf</source><year>2010</year><volume>9</volume><issue>3</issue><fpage>493</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1517/14740331003774078</pub-id><pub-id pub-id-type="pmid">20350282</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Piccirillo MC, Daniele G, Di Maio M, Bryce J, De Feo G, Del Giudice A, et al. Vinorelbine for non-small cell lung cancer. Expert Opin Drug Saf. 2010;9(3):493&#8211;510.<pub-id pub-id-type="pmid">20350282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14740331003774078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kajita</surname><given-names>J</given-names></name><name name-style="western"><surname>Kuwabara</surname><given-names>T</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>S</given-names></name></person-group><article-title>CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes</article-title><source>Drug Metab Dispos</source><year>2000</year><volume>28</volume><issue>9</issue><fpage>1121</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1016/S0090-9556(24)15196-3</pub-id><pub-id pub-id-type="pmid">10950859</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos. 2000;28(9):1121&#8211;7.<pub-id pub-id-type="pmid">10950859</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitzen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Puozzo</surname><given-names>C</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Brandely</surname><given-names>M</given-names></name><name name-style="western"><surname>Verweij</surname><given-names>J</given-names></name></person-group><article-title>Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study</article-title><source>Eur J Cancer</source><year>2010</year><volume>46</volume><issue>2</issue><fpage>266</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2009.10.031</pub-id><pub-id pub-id-type="pmid">19944596</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Kitzen JJ, Puozzo C, de Jonge MJ, Brandely M, Verweij J. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer. 2010;46(2):266&#8211;9.<pub-id pub-id-type="pmid">19944596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2009.10.031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schott</surname><given-names>AF</given-names></name><name name-style="western"><surname>Rae</surname><given-names>JM</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>KA</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>DF</given-names></name><name name-style="western"><surname>Sterns</surname><given-names>V</given-names></name><name name-style="western"><surname>Baker</surname><given-names>LH</given-names></name></person-group><article-title>Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme</article-title><source>Cancer Chemother Pharmacol</source><year>2006</year><volume>58</volume><issue>1</issue><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/s00280-005-0132-2</pub-id><pub-id pub-id-type="pmid">16283312</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 2006;58(1):129&#8211;35.<pub-id pub-id-type="pmid">16283312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-005-0132-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gusella</surname><given-names>M</given-names></name><name name-style="western"><surname>Pasini</surname><given-names>F</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>D</given-names></name><name name-style="western"><surname>Barile</surname><given-names>C</given-names></name><name name-style="western"><surname>Modena</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fraccon</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms</article-title><source>Cancer Chemother Pharmacol</source><year>2019</year><volume>83</volume><issue>3</issue><fpage>493</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1007/s00280-018-3751-0</pub-id><pub-id pub-id-type="pmid">30542768</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, et al. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. Cancer Chemother Pharmacol. 2019;83(3):493&#8211;500.<pub-id pub-id-type="pmid">30542768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-018-3751-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoh</surname><given-names>K</given-names></name><name name-style="western"><surname>Niho</surname><given-names>S</given-names></name><name name-style="western"><surname>Goto</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohmatsu</surname><given-names>H</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>K</given-names></name><name name-style="western"><surname>Kakinuma</surname><given-names>R</given-names></name><name name-style="western"><surname>Nishiwaki</surname><given-names>Y</given-names></name></person-group><article-title>High body mass index correlates with increased risk of venous irritation by vinorelbine infusion</article-title><source>Jpn J Clin Oncol</source><year>2004</year><volume>34</volume><issue>4</issue><fpage>206</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyh029</pub-id><pub-id pub-id-type="pmid">15121757</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol. 2004;34(4):206&#8211;9.<pub-id pub-id-type="pmid">15121757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jjco/hyh029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobili</surname><given-names>S</given-names></name><name name-style="western"><surname>Lavacchi</surname><given-names>D</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>G</given-names></name><name name-style="western"><surname>Vicini</surname><given-names>G</given-names></name><name name-style="western"><surname>Tassi</surname><given-names>R</given-names></name><name name-style="western"><surname>Landini</surname><given-names>I</given-names></name><etal/></person-group><article-title>Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience</article-title><source>Oncol Res</source><year>2020</year><volume>28</volume><issue>3</issue><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.3727/096504019X15755437099308</pub-id><pub-id pub-id-type="pmid">31806078</pub-id><pub-id pub-id-type="pmcid">PMC7851511</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, et al. Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience. Oncol Res. 2020;28(3):237&#8211;48.<pub-id pub-id-type="pmid">31806078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3727/096504019X15755437099308</pub-id><pub-id pub-id-type="pmcid">PMC7851511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ren</surname><given-names>T</given-names></name></person-group><article-title>The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis</article-title><source>Int J Clin Oncol</source><year>2020</year><volume>25</volume><issue>9</issue><fpage>1624</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1007/s10147-020-01707-9</pub-id><pub-id pub-id-type="pmid">32472208</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Xu K, Liu T, Zhang J, Zhou Y, Yang F, Ren T. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis. Int J Clin Oncol. 2020;25(9):1624&#8211;34.<pub-id pub-id-type="pmid">32472208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10147-020-01707-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livingston</surname><given-names>RB</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>GK</given-names></name><name name-style="western"><surname>Gralow</surname><given-names>JR</given-names></name><name name-style="western"><surname>Williams</surname><given-names>MA</given-names></name><name name-style="western"><surname>White</surname><given-names>R</given-names></name><name name-style="western"><surname>McGuirt</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><issue>4</issue><fpage>1395</fpage><lpage>1400</lpage><pub-id pub-id-type="doi">10.1200/JCO.1997.15.4.1395</pub-id><pub-id pub-id-type="pmid">9193331</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15(4):1395&#8211;400.<pub-id pub-id-type="pmid">9193331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.1997.15.4.1395</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jara-S&#225;nchez</surname><given-names>C</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Garc&#237;a-S&#225;enz</surname><given-names>JA</given-names></name><name name-style="western"><surname>Barnada</surname><given-names>A</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Aramburo</surname><given-names>A</given-names></name><name name-style="western"><surname>L&#243;pez-Vega</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group</article-title><source>Clin Breast Cancer</source><year>2003</year><volume>3</volume><issue>6</issue><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.3816/CBC.2003.n.004</pub-id><pub-id pub-id-type="pmid">12636884</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Jara-S&#225;nchez C, Mart&#237;n M, Garc&#237;a-S&#225;enz JA, Barnada A, Fern&#225;ndez-Aramburo A, L&#243;pez-Vega JM, et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer. 2003;3(6):399&#8211;404.<pub-id pub-id-type="pmid">12636884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3816/cbc.2003.n.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menz</surname><given-names>BD</given-names></name><name name-style="western"><surname>Stocker</surname><given-names>SL</given-names></name><name name-style="western"><surname>Verougstraete</surname><given-names>N</given-names></name><name name-style="western"><surname>Kocic</surname><given-names>D</given-names></name><name name-style="western"><surname>Galettis</surname><given-names>P</given-names></name><name name-style="western"><surname>Stove</surname><given-names>CP</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>SE</given-names></name></person-group><article-title>Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology</article-title><source>Br J Clin Pharmacol</source><year>2021</year><volume>87</volume><issue>2</issue><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1111/bcp.14372</pub-id><pub-id pub-id-type="pmid">32430968</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Menz BD, Stocker SL, Verougstraete N, Kocic D, Galettis P, Stove CP, Reuter SE. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol. 2021;87(2):227&#8211;36.<pub-id pub-id-type="pmid">32430968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/bcp.14372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><mixed-citation publication-type="other">Kim HY, Martin JH, Mclachlan AJ, Boddy AV. Precision dosing of targeted anticancer drugs&#8212;challenges in the real world. Transl Cancer Res. 2017:S1500&#8211;S11.</mixed-citation></ref><ref id="CR174"><label>174.</label><mixed-citation publication-type="other">FDA. Food and Drug Administration&#8212;Project Renewal. 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/about-fda/oncology-center-excellence/project-renewal">https://www.fda.gov/about-fda/oncology-center-excellence/project-renewal</ext-link>. Accessed 03 Feb 2025.</mixed-citation></ref></ref-list></back></article></pmc-articleset>